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ABSTRACT
Aplysinopsins are tryptophan-derived natural products that have been isolated from a variety of
marine organisms and have been shown to possess a range of biological activities. Initial
synthesis of a library of 50 aplysinopsin analogs revealed that of the 12 serotonin receptor
subtypes and 34 other CNS receptors, aplysinopsin analogs showed a high affinity for the 5HT2B and 5-HT2C receptor subtypes, with selectivity for 5-HT2B over 5-HT2C. Bromination at C4 and C-5 of the indole ring resulted in greater binding affinities, with Ki’s as low as 35 nM.
In addition, biological evaluation of the MAO-A and MAO-B inhibitory activities of these
compounds revealed some potent and selective MAO inhibitors. The most active compound 54,
which is brominated at C-6 and methylated at N-2′ and N-4′, showed strong inhibitory activity at
MAO-A (IC50 of 0.0056 μM) and had an SI of 80.24. Compounds 31, 51, and 54 were evaluated
in the chick anxiety-depression model to assess their in vivo efficacy. Compound 33 showed a
modest antidepressant effect at a dose of 30 nM/kg in the animal model.
In an effort to improve the in vivo efficacy of aplysinopsin analogs, we used an in silico ADME
predictor (QikProp) to evaluate and design a new series of analogs with improved ADME
properties. We also evaluated the metabolic stability of compound 53 and found that the
aplysinopsin scaffold does not appear to be overly susceptible to phase I metabolism, with a T1/2
of 61 minutes. We synthesized a new library of 12 analogs and evaluated their affinities at 46
CNS receptors and inhibitory activity at MAO-A and B. We found that N-benzyl aplysinopsin
analogs had moderate nanomolar-level affinities for 5-HT2B and 5-HT2C receptor subtypes. C-5
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Substituted compounds (88 and 89) had potent and selective inhibitory activity at MAO-A.
Compounds 83, 88, and 89 were evaluated in the chick-anxiety depression model to evaluate
their in vivo efficacy. Compound 83 showed modest antidepressant activity at a dose of 10
mg/kg and compound 89 showed potent antidepressant activity across all doses (1-10 mg/kg).

iii

DEDICATION
This work is dedicated to my parents and my wife.

iv

ACKNOWLEDGMENTS

I would like to acknowledge my advisor, Professor Jordan Zjawiony, for his continued
support and excellent guidance as I worked toward my degree. I would also like to thank my
committee members: Dr. Daneel Ferreira, Dr. Mark Hamann, and Dr. Ken Sufka. They were
always happy to provide guidance, advice, and helpful discussions whenever I asked.
I would like to extend a special thanks to Dr. Sufka and his lab of graduate and
undergraduate researchers for the hard work they put in while performing the chick anxietydepression assays. Also, Dr. Bryan Roth’s lab at the Psychoactive Drug Screening Program at
the University of North Carolina-Chapel Hill has been very accommodating in providing
screening of compounds at CNS receptors. I would also like to acknowledge Dr. Babu Tekwani
and Dr. Narayan Chaurasiya for their efforts in evaluating our compounds for their inhibitory
activities of MAO-A and MAO-B. Thanks are also due to Dr. Stephen Cutler and the COBRE
program here at Ole Miss that provided me with additional funding during my graduate studies.
For their help in performing the QikProp computation analysis, I would like to thank Dr. Robert
Doerksen and Gang Fu. Soon to be “Dr.” Joonseok Oh is greatly appreciated for his efforts in
maintaining our NMR facilities, as well as helping with constructing molecular docking figures.
I would also like to thank Ms. Casey Stauber and all of the staff in the Department of
Pharmacognosy office for their tireless work over the years. I do not think we would get much
accomplished on a day to day basis without their great efforts.
v

I would like to extend many thanks to my friends and colleagues that have come and
gone during my time in the Department of Pharmacognosy. That includes fellow graduate
students and post docs for their support and encouragement in the lab. I have been fortunate to
work with so many great scientists who were always happy to answer any question, regardless of
how big or small. Finally, I would like to thank my family: my parents, my sister and her family,
and my personal friends for their support and encouragement over the years. And last, but not
least I would like to thank my wife for being endlessly supportive and understanding of the time
I spent pursuing this degree. Thank you all very, very much.

vi

TABLE OF CONTENTS
ABSTRACT………………………………………………………………………….......

ii

DEDICATION…………………………………………………………………………… iv
ACKNOWLEDGMENTS………………………………………………………………..

v

LIST OF FIGURES………………………………………………………………………

viii

LIST OF TABLES……………………………………………………………………….. xii

CHAPTER 1 INTRODUCTION……………………………………………………….... 1
CHAPTER 2 IN VITRO STRUCTURE-ACTIVITY RELATIONSHIPS OF
APLYSINOPSIN ANALOGS AND THEIR IN VIVO EVALUATION IN THE
CHICK ANXIETY-DEPRESSION MODEL……………………………………………

21

CHAPTER 3 DESIGN OF A SECOND GENERATION OF APLYSINOPSIN
ANALOGS WITH IMPROVED IN VIVO EFFICACY………………………………...

57

LIST OF REFERENCES…………………………………………………………............ 105
APPENDIX………………………………………………………………………………

115

VITA…………………………………………………………………………………....... 134

vii

LIST OF FIGURES
Figure 1-1 Types of antidepressants ............................................................................................... 4
Figure 1-2 Recent natural product-derived drug approvals ............................................................ 6
Figure 1-3 Triptans used to treat migraine headaches .................................................................... 9
Figure 1-4 Serotonin biosynthesis .................................................................................................. 9
Figure 1-5 Serotonin receptor subtypes ........................................................................................ 11
Figure 1-6 Selective and reversible MAOIs ................................................................................. 13
Figure 1-7 Aplysinopsin dimer ..................................................................................................... 17
Figure 1-8 Structures of aplysinopsin and isoplysin A ................................................................. 18
Figure 2-1 5-HT2C ligands dexfenfluramine and lorcaserin ......................................................... 23
Figure 2-2 Known indoles and imidazolines with MAO inhibitory activities.............................. 26
Figure 2-3 General structure of aplysinopsin analogs. ................................................................. 26
Figure 2-4 Synthesis of 3-formylindoles ...................................................................................... 28
Figure 2-5 Synthesis of imidazolidinones 24, 27, 28, and 30 ....................................................... 28
Figure 2-6 Synthesis of imidazolidinones 23 and 26 .................................................................... 29
Figure 2-7 The synthesis of 3′-N-methylamineaplysinopsin analogs (76-80). ............................. 29
Figure 2-8 Binding affinity graphs for compounds 33, 34, and positive controls towards 5-HT2B
and 5-HT2C receptors. ................................................................................................................... 34
Figure 2-9 Reference compounds for MAO inhibitory assay ....................................................... 36
viii

Figure 2-10 Lead compounds selected for in vivo screening ....................................................... 41
Figure 2-11 Mean distress vocalizations as a rate/minute function (+/- SEM) for time in five
minute intervals. ............................................................................................................................ 41
Figure 2-12 The effects of social separation on mean DVocs (+/- SEM) in each drug treatment
condition under the anxiety-like phase (minutes 1-5)................................................................... 43
Figure 2-13 The effects of social separation on mean DVocs (+/- SEM) in each drug treatment
condition under the first depression-like phase (minutes 31-45). ................................................. 44
Figure 2-14 The effects of social separation on mean DVocs (+/- SEM) in each drug treatment
condition under the second depression-like phase (minutes 46-60). ............................................ 45
Figure 2-15 1H and 13C NMR spectra of compound 33. ............................................................... 50
Figure 2-16 1H and 13C NMR spectra of compound 51. ............................................................... 51
Figure 2-17 1H and 13C NMR of compound 54. ........................................................................... 52
Figure 3-1 QikProp-predicted water/octanol partition coefficients plotted against experimental
values. ........................................................................................................................................... 62
Figure 3-2 Possible sites of modification of aplysinopsins scaffold. ........................................... 62
Figure 3-3 Structures of proposed new library of aplysinopsin analogs ...................................... 70
Figure 3-4 Evaluation of the microsomal stability of compound 53 ............................................ 72
Figure 3-5 Metabolite structural hypothesis ................................................................................. 73
Figure 3-6 Synthesis of N-benzyl-3-formylindole intermediates ................................................. 74
Figure 3-7 Condensation of N-benzylaplysinopsin analogs 81-85 ............................................... 75
ix

Figure 3-8 Synthesis of compounds 86, 88, and 89 ...................................................................... 76
Figure 3-9 Synthesis of compounds 87 and 90-92........................................................................ 76
Figure 3-10 Binding affinity graphs for compound 83 positive controls towards 5-HT2B and 5HT2C receptors. ............................................................................................................................. 78
Figure 3-11 Binding affinity graphs for compounds 83, 84, and positive controls towards

5-

HT3. .............................................................................................................................................. 79
Figure 3-12 Binding affinity graphs for compounds 82, 84, and positive controls towards KOR.
....................................................................................................................................................... 80
Figure 3-13 MDR-1 susceptibility assay ...................................................................................... 83
Figure 3-14 MDR-1 susceptibility of compounds 83, 88, and 89. ............................................... 84
Figure 3-15 The effects of 83 on isolation-induced distress vocalizations (DVocs) for the final 30
min of the isolation period. Values represent mean ±SEM (n= 17-18). * indicates significant
increase in DVoc compared with vehicle condition. .................................................................... 86
Figure 3-16 The effects of 89 on isolation-induced distress vocalizations (DVocs) for the final 30
min of the isolation period. Values represent mean ±SEM (n = 17-18). * indicates significant
increase in DVoc compared with vehicle condition. .................................................................... 87
Figure 3-17 Crystal structure of 5-HT2B with ergotamine bound. ................................................ 90
Figure 3-18 Two dimensional representation of ligand interactions in 5-HT2B binding pocket. 91
Figure 3-19 Crystal structures of MAO isoforms A and B in complex with inhibitors clorgyline
and deprenyl. ................................................................................................................................. 93
x

Figure 3-20 1H and 13C NMR spectra of compound 83. ............................................................... 97
Figure 3-21 1H and 13C NMR spectra of compound 88. ............................................................... 98
Figure 3-22 1H and 13C NMR spectra of compound 89. ............................................................... 99

xi

LIST OF TABLES
Table 1-1 FDA approved marine natural product drugs ................................................................. 8
Table 1-2 Structures of aplysinopsins 1-6 .................................................................................... 15
Table 1-3 Structures of aplysinopsins 7-11 .................................................................................. 16
Table 1-4 Structures of aplysinopsins 12-15 ................................................................................ 16
Table 2-1 List of additional CNS receptors evaluated. ................................................................. 25
Table 2-2 Synthesis route to aplysinopsin analogs (31-65) .......................................................... 31
Table 2-3 Selected serotonin receptor subtype binding affinities ................................................. 33
Table 2-4 Aplysinopsin analogs tested for inhibition (IC50) of human MAO-A and MAO-B
activities in vitro ........................................................................................................................... 37
Table 3-1 QikProp properties and descriptors. ............................................................................. 64
Table 3-2 Selected QikProp values for compounds 81-92 ........................................................... 69
Table 3-3 Selected CNS receptor in vitro binding affinities for compounds 81-92. .................... 77
Table 3-4 Aplysinopsin analogs 81 - 92 tested for inhibition of human MAO-A and MAO-B
activities. ....................................................................................................................................... 81
Table 4-1 Secondary in vitro binding data from compounds 31-80 at all 12 5-HT subtypes..... 129

xii

CHAPTER 1
INTRODUCTION
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1. Treatment of depression
The development of treatments for central nervous system disorders is a vast sector of
research. The World Health Organization estimates that at the current rate of increase,
depression will be the second most disabling condition in the world by 2020.1 Given this
forecast, it is no surprise that pharmaceutical companies are spending vast amounts of time and
resources pursuing new leads to treat CNS disorders such as depression and anxiety.2
The history of the pharmacological treatment of depression has experienced two
revolutionary periods. The first was the 1950s, a decade that saw the launch of the first
monoamine oxidase inhibitor, iproniazid, as well as the first of the tricyclic antidepressants used
for treatment, imipramine, as shown in Figure 1-1.3 The second major revolutionary period
occurred in the 1980s with the development of the selective serotonin reuptake inhibitor Prozac
(fluoxetine), which has become one of the best-selling pharmaceuticals of all time. From the
1950s until today, there have been four general classes of antidepressant drugs used in treatment,
each with varying degrees of success and side effect profiles. The four broad categories are:
tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), selective serotonin
reuptake inhibitors (SSRIs), and atypical antidepressants.
Tricyclic antidepressants primarily function by blocking the reuptake of serotonin and
norepinephrine via blockade of the serotonin transporter (SERT) and norepinephrine transporter
(NET). These actions result in an increase of the neurotransmitters in the synaptic cleft and thus
an increase in neurotransmission.4 In addition to the inhibition of reuptake, TCAs also exhibit
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antagonistic activity at several other receptors, including serotonin subtypes,5 NMDA,6 sigma,7
histamine,8 and acetylcholine receptors.5 This wide array of activity/lack of selectivity likely
contributes to the side effects of TCAs. Despite being the first antidepressants on the market,
TCAs are used less today, as they have been replaced by drugs with better safety and side effect
profiles. However, they remain in use for severe cases of depression that do not respond to other
classes of antidepressants.9
Monoamine oxidase inhibitors were discovered by happenstance when researchers
studying the hydrazine iproniazid (Figure 1-1) for the treatment of tuberculosis found that
patients who received the drug saw markedly improved psychiatric profiles. Monoamine
oxidase (MAO) is an enzyme responsible for the deactivation of neurotransmitters like serotonin,
dopamine, and norepinephrine. MAOIs cause a reduction in this enzymatic activity, which
results in an increased concentration of neurotransmitters. A more detailed discussion
concerning the use of MAOIs in the treatment of depression follows later in this chapter.
Selective serotonin reuptake inhibitors are, as their name implies, drugs that selectively
inhibit the reuptake of serotonin from the synapse, much like TCAs. The difference is that they
are selective only for serotonin, thus reducing the aforementioned problematic side effects that
plague TCAs. The most well know SSRI is Prozac (fluoxetine), shown in Figure 1-1. Unlike
TCAs and MAOIs, which were discovered serendipitously, SSRIs were borne out of work
surrounding the serotonergic hypothesis, or the serotonin theory, of depression. Essentially this
theory postulates that a depletion of serotonin in the brain is responsible for depression.
Following this theory, SSRIs, and fluoxetine in particular, became the first rationally designed
antidepressants on the market. Fluoxetine and other SSRIs were designed to act on a specific
3

target (SERT) and to avoid unwanted binding affinities for other receptors/targets, which could
lead to the side effects that plagued other antidepressant drug classes. SSRIs possess a much
better side effects profile and thus have become some of the best selling drugs in the world,
making drugs like Prozac, Celexa (citalopram), and Zoloft (sertraline) household names. These
drugs were primary options for the treatment of depression until the recent development of
atypical antidepressants.

Imipramine
(TCA)

Iproniazid
(MAOI)

Fluoxetine
(SSRI)

Mirtazapine
(Atypical)

Figure 1-1 Types of antidepressants
Atypical antidepressants are newer drugs that function in different ways from the
previously described classic antidepressants. Drugs categorized as atypical do not necessarily
share the same mechanism of action. For example, Wellbutrin (buproprion) acts as a type of
stimulant more so than a traditional antidepressant. It does so by inhibiting the reuptake of
4

dopamine and norepinepherine. Another major subgroup of atypical antidepressants, which are
of special interest in regards to this dissertation, are drugs that act as agonists/antagonists of
specific serotonin receptor subtypes. Buspar (buspirone) and Remeron (mirtazapine) are
agonists of serotonin receptor subtype 5-HT1A. Cymbalta (duloxetine) is a representative of the
selective serotonin and norepinepherine reuptake inhibitors (SNRIs), which are similar to SSRIs,
but also act on norepinepherine uptake in the synaptic cleft. The side effects of atypical
antidepressants vary from group to group, as they all have different mechanisms of action.
However, in general, they have displayed better side effect profiles and toleration by patients.
Despite the increased safety profile of SSRIs and atypical antidepressants, there are still
issues to solve when it comes to antidepressant drug design. First and foremost is the delay in
onset of efficacy, which often takes weeks. In addition, it is currently estimated that roughly
30% of patients do not respond to currently available treatment options.10 Until these issues are
solved, the search for safer and more efficacious antidepressant drugs leads will continue.
Natural products as drug sources
Natural products have long been a source of new drugs. In 2003, it was reported that
61% of small-molecule new chemical entities introduced as drugs from 1981 to 2002 could be
contributed to natural products.11 The last decade alone has seen the launch of a broad range of
natural product-derived drugs, as shown in Figure 1-2. These include the antibacterial agent
Finibax (doripenem), which was launched in 2005 by Shiongi Co. and is used to treat serious
kidney and urinary tract infections.
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Eraxis (anidulafungin) 2006

Finibax (doripenem) 2005

Votrient (pazopanib) 2009

Figure 1-2 Recent natural product-derived drug approvals
The antifungal Eraxis (anidulafungin) was approved by the FDA in 2006 and is marketed by
Pfizer. It is commonly used to treat Candida infections in the blood, stomach, or esophagus. The
natural product mimic anticancer agent Votrient (pazopanib), launched in 2009, is used against
late-stage kidney cancers as well as soft tissue sarcomas. These are just a few examples of
natural product-derived drugs to recently gain FDA approval. There are several excellent
reviews which cover the broad number and diversity among natural product-derived drug leads
either on the market or in the late stages of clinical trials.12
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Marine natural products
Marine natural products have been a rich source for structurally diverse bioactive
secondary metabolites with unique characteristics. More accessible SCUBA technology has
made collection easier, which in turn has allowed for increased exploration of marine
environments over the last few decades. This has led to the identification of a large number of
novel bioactive compounds. There are currently seven marine natural products that are FDA
approved, as shown in Table 1-1, the majority of which are anticancer agents. In addition, there
are numerous others undergoing further development in clinical trials.13
One particular class of marine natural products to garner significant attention from the
research community is the marine indole alkaloids. This interest is mostly due to their promising
neuromodulatory biological activities. These compounds are structurally similar to endogenous
neurotransmitters, so it should come as no surprise that they often possess central nervous system
(CNS) activity. There are several indole alkaloids on the market to treat various CNS disorders,
such as the triptans, which are used to treat migraines (Figure 1-3).14 Most drugs in this class are
agonists of serotonin receptor subtypes 5-HT1B and 5-HT1D. It is clear that the structural
homology between these indole alkaloids and the body’s natural neurotransmitters opens up a
therapeutic niche to possibly treat CNS disorders such as depression and anxiety.
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Name

Natural Source

Treatment

Brentuximab vedotin (SGN-35)

Cyanobacterium

Cancer15

Trabectedin (ET-743)

Tunicate

Cancer16

Cytarabine (Ara-C)

Sponge

Cancer17

Eribulin mesylate (E7389)

Sponge

Cancer18

Ziconotide

Cone Snail

Pain19

Omega-3-acid ethyl esters

Fish

Hypertriglyceridemia20

Vidarabine (Ara-A)

Sponge

Antivrial21

Table 1-1 FDA approved marine natural product drugs
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Figure 1-3 Triptans used to treat migraine headaches
Targeting serotonin receptor subtypes
Serotonin, or 5-hydroxytryptamine (5-HT), is an indoleamine with a chemical structure
similar to the amino acid tryptophan. Tryptophan actually serves as a precursor in the
biosynthetic pathway of serotonin via a two-step pathway, as shown in Figure 1-4. The first, and
rate-limiting step, involves the hydroxylation of position C-5 of tryptophan. The final step is the
decarboxylation of 5-hydroxytryptophan to serotonin.

Figure 1-4 Serotonin biosynthesis
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As mentioned previously, the serotonin receptor system has been widely recognized as a
key element in the pathophysiology of depression and as a mediator of the therapeutic action of
antidepressants.22 Dysfunction of the serotonin receptor system has been implicated in a wide
array of psychiatric disorders, including anxiety, depression, and schizophrenia.23 The role of
serotonin in mood control, appetite, sleep, and pain has also been extensively studied.24 The life
cycle of serotonin can be simplified to the following steps. First, serotonin is released into the
synaptic cleft where it binds to pre- or postsynaptic serotonin receptor subtypes. Next, it is
released and subsequently taken up by SERT. Then, it is recycled into the vesicular pool or
degraded by monoamine oxidase A.
Serotonin functions in the body are mediated by a large family of receptors.25 There have
been seven families of serotonin receptors identified, 5-HT1 – 5-HT7. Each of these is further
subdivided into subtypes. Overall there are 14 subtypes of serotonin receptors, as shown in
Figure 1-5. All of these subtypes, except for 5-HT3, are G-protein coupled receptors (GPCR). 5HT3 is a ligand-gated ion channel receptor.
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5-HT Receptors
5-HT1

5-HT2

5-HT3

5-HT4

5-HT5

5-HT1A 5-HT2A

5-HT5A

5-HT1B 5-HT2B

5-HT5B

5-HT6

5-HT7

5-HT1D 5-HT2C
5-HT1E
5-HT1F
Figure 1-5 Serotonin receptor subtypes
Owing to the serotonin receptor subtypes sharing a high degree of structural homology,
research efforts are aimed at finding receptor ligands with a high affinity and selectivity among
serotonin receptor subtypes. The discovery of potent and selective ligands could provide not
only drug leads but also increased understanding of the functions of each receptor subtype.
Owing to the structural homology between serotonin and marine indole alkaloids, these natural
products and their derivatives represent interesting scaffolds to explore new leads for the
treatment of CNS disorders.
MAO inhibitors
As mentioned previously, MAOIs are another class of drugs that have received
significant use in the clinical setting to treat CNS disorders. After their discovery in the 1950s,
they were used as first line treatment for depression for several decades. However, their

11

extensive side effects and food and drug interactions led to a decline in use. The dietary
restrictions imposed by the FDA include the following common foods to avoid while using
MAOIs: aged cheeses and meats, draft beer, sauerkraut, kimchee, soybean products, and wine.
In addition, the list of drugs to avoid is also quite long, but in general, the idea is to avoid
dangerous drug-drug interactions that could lead to the development of serotonin syndrome.
Serotonin syndrome results when an MAOI is taken in combination with serotonin enhancing
drugs like SSRIs or St. John’s wort. These restrictions, coupled with the development of new
and safer antidepressants, led MAOIs to be relegated to third or fourth-line treatment options for
depression in the last two decades.
There are two isoforms of MAO: MAO-A and MAO-B.26 They have been found to vary
in their distribution in the body, but both are found in various regions in the brain. The two
isoforms also have different preferred substrates. The preferred MAO-A substrates are serotonin
and norepinephrine, while MAO-B preferentially breaks down phenylethylamine and histamine.
Dopamine and tyramine are substrates for both isoforms.
MAOIs can be classified into three categories: nonselective, selective, and reversible
inhibitors. The early MAO inhibitors such as phenelzine were neither reversible nor selective,
hence, their extensive side effects profile and dietary restrictions. Newly developed selective
and reversible MAOIs have given this class of antidepressants new life. These selective
inhibitors allow the other isoform to metabolize substances such as tyramine, thus avoiding
potentially harmful side effects. Ligands that bind reversibly can also be displaced by other
substrates, such as the aforementioned tyramine. Thus, selective and reversible MAOIs could
potentially be used without the cumbersome dietary restrictions of older MAOIs. Selegiline
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(Figure 1-6) is an example of a selective and reversible MAO-B inhibitor, which has been
approved to be used in a transdermal patch system that requires no dietary restrictions. Selective
and reversible inhibitors of MAO-A (RIMAs) like moclobemide are on the market
internationally but not currently in the US. Like their selective and reversible MAO-B
counterparts, they too lack the cumbersome dietary restrictions that made older MAOIs less
appealing to doctors and patients. These new classes of MAOIs increased the demand for new
drugs that are potent and selective for one MAO isoform and which also bind reversibly.

Selegiline
MAO-B inhibitor

Moclobemide
MAO-A inhibitor

Figure 1-6 Selective and reversible MAOIs
Aplysinopsins
Aplysinopsins are tryptophan-derived marine natural products that were first isolated in
1977 from several Indo-Pacific sponge species from the genera Thorecta.27 Those species have
since been reassigned as the Aplysinopsis genera. Since their initial isolation, aplysinopsins have
been isolated from sponges in several geographic locations such as the Caribbean28 and the
Mediterranean.29 In addition to being isolated from sponges, aplysinopsins have also been
isolated from corals,30 mollusks,31 and sea anemones.32
The general structure of aplysinopsin derivatives is shown in Table 1-2. It is comprised
of an indole moiety coupled with an imidazolidinone. There are several common themes among
natural derivatives of aplysinopsins. First is the variation in the bromination pattern on the
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indole moiety. In all but one of the naturally occurring aplysinopsin derivatives, bromination
occurs at C-6. The only exception is that of 5,6-dibromo-2′-demethylaplysinopsin (1), which is
brominated at C-5 and C-6.33 The number and position of N-methylations on the C ring can also
vary. There have been compounds isolated with one (2, 3), two (4, 5), and three (6) methyl
groups present.
The stereochemistry of the C-8-C-1′ double bond is another source of variation among
natural derivatives. The earliest reports of aplysinopsins and the subsequent biological
investigations either did not address this issue, or just described the aplysinopsin analog as the E
geometrical isomer. The work of Guella et al. nicely elucidated this issue and provided an NMR
technique by which the two isomers may be readily differentiated.34 They found that one can use
the 1H, 13C heteronuclear coupling constants between H-8 and C-5′ to determine the predominant
isomer. A larger coupling constant (9 - 11 Hz) indicates the presence of the E isomer, while the
coupling constant is usually smaller (4 - 5.5 Hz) for the Z isomer.
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General Structure of Aplysinopsin Analogs
CMPD

Name

R1

R2

R3

R4

1

5,6-dibromo-2′demethylaplysinopsin

4,6-Br

H

H

CH3

2

2′-de-N-methyl-aplysinopsin

H

H

H

CH3

3

6-bromo-2′-de-Nmethylaplysinopsin

6-Br

H

H

CH3

4

6-bromoaplysinopsin

6-Br

CH3

H

CH3

5

6-bromo-4′-de-Nmethylaplysinopsin

6-Br

CH3

H

H

6

methylaplysinopsin

H

CH3

CH3

CH3

Table 1-2 Structures of aplysinopsins 1-6
1′,8-dihydroaplysinopsins and C-1′ substituted derivatives have also been isolated (7-11)
(Table 1-3). The oxidation state of the C ring is a source of variety, as derivatives (12, 13) have
been isolated with different oxidation states at C-3′ of the imidazolidinone moiety (Table 1-4).34a
Analogs which are substituted at N-1′ have been reported from sponges (14)30 and anthozoans
(15).35 Lastly, aplysinopsin dimers have been isolated from a coral species, as seen in Figure
1-7.36
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CMPD

Name

R1

R2

7

1′,8-dihydroaplysinopsin

H

H

8

6-bromo-1',8-dihydroaplysinopsin

6-Br

H

6-Br

OH

6-Br

OCH3

6-Br

OCH2CH3

9
10

11

6-bromo-1'-hydroxy-1',8dihydroaplysinopsin
6-bromo-1'-methoxy-1',8dihydroaplysinopsin
6-bromo-1'-ethoxy-1',8dihydroaplysinopsin

Table 1-3 Structures of aplysinopsins 7-11

CMPD

Name

R1

R2

R3

12

3′-deimino-3′-oxoaplysinopsin

H

O

H

13

6-bromo-3′-deimino-3′oxoaplysinopsin

6-Br

O

H

14

N-propionylaplysinopsin

H

NH

OCCH2CH3

15

N-methylaplysinopsin

H

HH

CH3

Table 1-4 Structures of aplysinopsins 12-15
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Figure 1-7 Aplysinopsin dimer

Biological activity of aplysinopsins
Aplysinopsins have been shown to possess a wide range of biological activities. Their
first reported biological activity was antitumor activity seen in mice. Using a bioassay guided
fractionation approach, aplysinopsin (16) (Figure 1-8) was isolated from the sponge Verongia
spengelli.37 In in vitro assays, compound 16 was shown to have an inhibitory activity against
P388 lymphocytic leukemia in mice at a dose of 200 mg/kg. Another aplysinopsin analog,
isoplysin A (17), was also found to possess some antineoplastic activity. It was found to inhibit
the growth of murine lymphoma LH-1210 cells, with an IC50 value of 11.5 μg/mL. In the same
study, aplysinopsin and methylaplysinopsin (6) also showed moderate cytotoxicity against the
LH-1210 cell line with IC50 values of 2.3 and 3.5 μg/mL, respectively.35
A series of aplysinopsin analogs, isolated from the sponge Smenospongia aurea, were
evaluated for their in vitro antimalarial activity.38 These compounds were tested against
Plasmodium falciparium, and several compounds showed moderate activity and selectivity. 6Bromoaplysinopsin (4) had an IC50 of 0.34 μg/mL. Isoplysin A (17) and 6-bromo-2′-de-N-
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methylaplysinopsin (3) also showed moderate activity, with IC50’s of 0.97 and 1.1 μg/mL,
respectively. However, in subsequent in vivo testing, compound 4 was found to be inactive.39

Figure 1-8 Structures of aplysinopsin and isoplysin A
Marine organisms have been a rich source of antimicrobial drug leads in the past,40 so it
is no surprise that aplysinopsins have been evaluated for their potential antimicrobial activities.
There are several reports of mostly weak inhibitory properties against various microbes. A
mixture of 6-bromoaplysinopsin (4) and 6-bromo-4′-de-N-methylaplysinopsin (5) was found to
inhibit Bacillus subtillis,41 and in a separate report, compound 4 was found to also inhibit growth
of the fungus Trichophyton mentagrophytes.42 In addition, compounds 16 and 4 were found to
inhibit the growth of Staphylococcus aureus.
Despite the aforementioned biological activities, our main interest in aplysinopsins lies in
their ability to modulate neurotransmissions. Since their discovery, their structural similarity to
endogenous neurotransmitters has led to them being investigated for neuromodulatory activity.
As mentioned previously, several marine indole alkaloids have already been found to have
potential to treat depression by acting on various neurotransmitters. Aplysinopsins have been
implicated in acting on both the serotonin receptor system as well as the monoamine oxidase
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system.
An early study found that methylaplysinopsin (6) was able to inhibit MAO activity in a
mouse brain homogenate model. In the same study, an evaluation of the binding kinetics
revealed this inhibition to be short-term and reversible.43 Compound 6 had a moderate ability to
displace serotonin with an IC50 of 160 μM. Methylaplysinopsin was also evaluated for its ability
to influence norepinephrine uptake and was found to have no significant effect.
A 2002 study by Hu et al. evaluated aplysinopsin analogs isolated from the Jamaican
sponge Smenospongia aurea for their affinity for human serotonin 5-HT2 receptor subtypes 5HT2A and 5-HT2C.38 These subtypes were of special interest due to their involvement in the
pathophysiology of anxiety and depression. The 5-HT2 receptor subfamily share highly
conserved sequences (80%),25 thus the study was aimed at not only finding ligands with high
affinity, but also selectivity among the two receptor subtypes studied.

Their SAR analysis

pointed to a significance of functional groups at C-6, C-2′ and C-3′ in binding to human 5-HT2
receptors. Bromination at C-6 and the increased length of the alkyl chain at C-3′ enhanced
affinity. In addition, the bromination enhanced the selectivity for 5-HT2C over the 5-HT2A
subtype. On the other hand, the methylation at N-2′ increased affinity to the 5-HT2A receptor.
In another study of a synthetic library of aplysinopsin analogs, it was shown that the
aplysinopsin scaffold can be manipulated such that selection between 5-HT2A and 5-HT2C can be
achieved.44 Cummings et al. found that alkylation at N-2′ and N-4′ coupled with various
halogenation patterns can yield highly selective ligands. More specifically, substitution at C-6
with a chlorine or bromine resulted in a preference for 5-HT2C binding. However, if C-6 is left
unsubstituted or substituted with a fluorine, there was a preference for 5-HT2A. It is proposed
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that the size of the halogen plays a key role in this selectivity.
There are few reports of in vivo evaluations of aplysinopsin analogs, especially
concerning their neuromodulatory activity. In a recent study, aplysinopsin (16) was evaluated in
the Porsolt forced swim test but did not exhibit any antidepressant activity.45 This result
highlights an important problem in CNS drug discovery, i.e., compounds that possess potent in
vitro activities but fail to show significant efficacy in animal models due to poor absorption,
distribution, metabolism, excretion and toxicity (ADMET) properties. CNS agents must pass
through the blood-brain barrier (BBB), and this requirement leads to the failure of many CNS
drug candidates. For this reason, assessment of BBB permeability should be done as early as
possible in drug discovery. There are several ways to evaluate BBB permeability, including in
vivo, in silico, and in vitro methods.46
As mentioned previously, the number of people diagnosed with depression and/or
complications arising from depression is growing, fueling a need for new antidepressant drugs
which are more efficacious as well as safer. The current treatment options are not effective in
large segments of the population, and, even in those individuals who do respond to treatment, it
often takes weeks to see the effects.47 Despite these initial negative results in in vivo testing,
aplysinopsins represent a promising scaffold for the development of potential therapeutically
valuable compounds to treat depressive disorders.
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CHAPTER 2
IN VITRO STRUCTURE-ACTIVITY RELATIONSHIPS OF APLYSINOPSIN ANALOGS
AND THEIR IN VIVO EVALUATION IN THE CHICK ANXIETY-DEPRESSION MODEL

Adapted from: Lewellyn, K.; Bialonska, D.; Chaurasiya, N. D.; Tekwani, B. L.; Zjawiony, J. K.
Bioorg. Med. Chem. Lett. 2012, 22, 4926 and Lewellyn, K.; Bialonska, D.; Loria, M. J.; White, S.
W.; Sufka, K. J.; Zjawiony, J. K. Biorg. Med. Chem. 2013, 21, 7083 with permission.
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2. Introduction
Depression effects nearly 1 in 10 adults in the US according to a CDC study.48 The
WHO estimates that by 2020 depression will be the second most disabling condition in the
world.1 Based on these statistics there is a clear need for new drug candidates for the treatment
of depression.49 Aplysinopsins have received considerable attention as promising
neuromodulators, with significant affinity to serotonin receptors38 and the potential to inhibit
MAO activity.43 Since these two mechanisms are known to be involved in antidepressant action,
aplysinopsins represent potentially useful candidates in antidepressant drug development.
Dysfunction of the serotonin receptor system can lead to a wide array of psychiatric
disorders including anxiety, depression and schizophrenia.23 The role of serotonin in mood
control, appetite, sleep, thermoregulation and pain has also been extensively studied.24 In
addition to CNS disorders, the 5-HT receptor system has also been implicated in disorders of the
cardiovascular and pulmonary systems.50 With the increased understanding of how serotonin
and its receptors function in multiple systems throughout the body, we must take into account the
potentially wide ranging side effects of drugs on systems other than the CNS. This problem
further underscores the need to develop drug leads which are potent, but also highly selective
among the serotonin receptor subtypes.
A group of aplysinopsins isolated the from Jamaican sponge Smenospongia aurea
exhibited an affinity for human serotonin 5-HT2 receptor subtypes 5-HT2A and 5-HT2C expressed
in a mammalian cell line.38 These subtypes were of interest as possible targets in the treatment
of schizophrenia, depression, anxiety, and obesity.51 It has been shown that 5-HT2C receptor
knockout mice exhibit obesity, epilepsy, and cognitive disorders.52 The three receptor subtypes
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of the 5-HT2 family (2A, 2B, 2C) share highly conserved sequences (80%); thus, designing
ligands which are potent and selective remains a challenge.
A major problem in the development of 5-HT2C ligands has been a lack of selectivity
over 5-HT2A and 5-HT2B subtypes. Activation of 5-HT2A receptors may lead to hallucinations
and activation of 5-HT2B can result in cardiac insufficiency and pulmonary hypertension (e.g.
fenfluramine case).53 Thus, discovery of highly selective 5-HT2C ligands could provide new and
safer drugs. A good example of this is lorcaserin (Belviq) (Figure 2-1), a recently approved antiobesity drug.54 It was developed based on the potent 5-HT2C agonist dexfenfluramine, which
was approved as a weight loss agent in 1996. However, cardiovascular side effects stemming
from 5-HT2B agonist activity led to dexfenfluramine’s withdrawal from the market just one year
later.55 Using a medicinal chemistry approach, lorcaserin was developed to retain its potent 5HT2C agonism, but also be selective for 5-HT2C over 5-HT2B. Lorcaserin has high affinity (Ki =
15 nM) to human 5-HT2C receptors and exhibits 18- and 104-fold selectivity over 5-HT2A and 5HT2B, respectively.56

Dexfenfluramine

Lorcaserin

Figure 2-1 5-HT2C ligands dexfenfluramine and lorcaserin
To date, there has been little published regarding the structure activity relationship
between aplysinopsin analogs and their serotonin binding affinities and selectivity. A
preliminary SAR analysis of naturally occurring aplysinopsins pointed to significance of
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functional groups at positions 6, 2′ and 3′ in binding to human 5-HT2 receptors.38 Bromination at
C-6 and the increased length of the alkyl chain at C-3′ enhanced affinity. In addition, the
bromination enhanced the selectivity to 5-HT2C over the 5-HT2A subtype. On the other hand,
methylation at C-2′ increased affinity to the 5-HT2A receptor. In another study of a synthetic
library of aplysinopsin analogs, it was shown that the aplysinopsin scaffold can be manipulated
such that selection between 5-HT2A and 5-HT2C can be achieved.44 Cummings et al. found that
alkylation at C-2′ and C-4′ coupled with various halogenation patterns can yield highly selective
ligands. More specifically, C-6 substitution with a chlorine or bromine resulted in a preference
for 5-HT2C binding. However, if C-6 is left unsubstituted or substituted with a fluorine there was
a preference for 5-HT2A. It is proposed that the size of the halogen plays a key role in this
selectivity. Both of these studies are promising results that suggest a potential therapeutic value
for aplysinopsin analogs. However, both also use a limited number of analogs and only evaluate
affinity at 5-HT2A and 5-HT2C, ignoring potential binding at not only other serotonin receptor
subtypes, but also at other CNS receptors. The small library size also limits the amount of SAR
information that is able to be gathered from the study. We will add to these promising reports by
working with a larger library of compounds and evaluating their activity on a larger number of
serotonin receptor subtypes and thirty four other CNS receptors as well (see Table 2-1).
Evaluating the library at a large number of CNS receptors beyond serotonin receptor subtypes
may reveal potentially deleterious off-site activity.
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Alpha1A
Beta2
D5
H4
MOR
Alpha1B
Beta3
DAT
KOR NET
Alpha1D BZP Rat Brain Site
DOR
M1
SERT
Alpha2A
D1
GABAA M2 Sigma1
Alpha2B
D2
H1
M3 Sigma2
Alpha2C
D3
H2
M4
Beta1
D4
H3
M5
Table 2-1 List of additional CNS receptors evaluated.
Monoamine oxidase inhibitors (MAOIs) initially were first line medications in the
treatment of depressive illness, however, due to serious side effects, the interest in these drugs
diminished.57 When the two isoforms, MAO-A and MAO-B, were discovered, interest was
renewed in their potential therapeutic use and several new generations of selective MAO
inhibitors have been developed.58 Today, much more is known about the use of selective MAO
inhibitors to treat various mental disorders such as depression, anxiety, and Parkinson’s and
Alzheimer’s disease.59 Owing to this increased understanding of neurological disease states,
there is an increased interest in development of potent and selective MAOIs.
Structurally, aplysinopsins are made up of two distinct moieties: an indole and an
imidazolidinone ring. The indole scaffold is known to contribute to MAO inhibitory activities
(see Figure 2-2), and many analogs have been prepared using this scaffold.60 Furthermore, a
recent study has shown that imidazolines possess potent and selective activity at both MAO
isoforms.61 Based on this data and the previous study examining the effects of
methylaplysinopsin (6) on MAO activity,43 it is clear that the aplysinopsin scaffold represents a
potential source of new MAOI drug candidates.
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MAO-B IC50 = 0.06 μM

MAO-B Ki = 1.49 μM

Figure 2-2 Known indoles and imidazolines with MAO inhibitory activities.
In the present study, 50 aplysinopsin analogs (31-80) (Table 2-2) have been obtained
synthetically and screened for affinity to 12 human serotonin as well as 34 additional CNS
receptors. The library was also evaluated for inhibitory activity at MAO isoforms A and B.
Tested analogs varied in the substitution pattern of the indole ring and the imidazolidinone
moiety (see Figure 2-3). The indole ring was either non-brominated or brominated in the 4, 5, 6,
or 7 positions. The imidazolidinone was not substituted, or methylated in one (2′, 3′, 4′), two (2′,
3′; 2′, 4′; and 3′, 4′), or three positions (2′, 3′, and 4′).

Figure 2-3 General structure of aplysinopsin analogs.
There have been a limited number of studies examining the biological activities of
aplysinopsins in vivo. The number of neuromodulatory studies is even less. One early study did
use an ex vivo system to examine MAO inhibition and perform preliminary pharmacokinetic
studies.43 They found that the MAO activity was short-term and reversible and that the
biological activity correlated with the disappearance of methylaplysinopsin from the plasma. In
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a more recent study, aplysinopsin (51) was tested in the Porsolt forced swim test but did not
exhibit any antidepressant activity.45 Considering these results, following in vitro evaluation of
our library, we wanted to evaluate several lead compounds in an appropriate animal model to
determine if their in vitro efficacy translated to an in vivo model. Three compounds (33, 51, and
54) were screened in the chick anxiety-depression model.62 This hybrid social isolation stress
paradigm is capable of screening for both anxiolytic and anti-depressant activity.

Synthesis of aplysinopsin analogs
Synthesis of 3-formylindoles
Aplysinopsins consist of an indole moiety coupled with a corresponding imidazolidinone.
There have been several papers published reviewing the various synthesis strategies to obtain
aplysinopsin analogs.63 Most synthesis strategies involve the synthesis of the desired 3formylindole followed by condensation with the appropriate imidazolidinone.
The 3-formylindoles 18-22 were initially prepared using a variation of the BatchoLeimgruber indole synthesis64 as shown in Figure 2-4. Briefly, the appropriate
bromonitrotoluenes were added to a mixture of N,N-dimethylformamide dimethyl acetal and
pyrrolidine in DMF and heated to 110°C until the substrate was consumed. The resulting crude
enamines were reduced and cyclized with zinc in acetic acid. The brominated indoles were
converted to 3-formylindoles via a Vilsmeier-Haack reaction. In some cases, for subsequent
synthesis of larger quantities of aplysinopsin analogs, commercially available 3-formylindoles
were used.
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Figure 2-4 Synthesis of 3-formylindoles

Synthesis of imidazolidinones
The synthesis of the imidazolidinones 23-30 were carried out according to published
procedures as shown in Figures 2-4 - 2-5, except for creatinine (24), which was available
commercially. Briefly, creatinine (24) was methylated using iodomethane to yield 1,3-dimethyl2-imino-4-imidazolidinone (28). Compound 28 was subsequently refluxed in methanol to yield
the isomerized 1-methyl-2-(methylamino)-2-imidazolin-4-one (27). Compound 27 was
methylated to yield the trimethylated 1,3-dimethyl-2-(methylimino)- 4-imidazolidinone (30).65

Figure 2-5 Synthesis of imidazolidinones 24, 27, 28, and 30
Compound 23 was synthesized from guanidinoacetic acid according to the procedure
from Bengelsdorf as shown in Figure 2-6.66 Compound 23 was methylated to yield 26. Our
attempts to obtain the imidazolidinone 25 following the published procedure65 and the
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condensation of glyoxal with N-methylguanidine67 failed.

Figure 2-6 Synthesis of imidazolidinones 23 and 26
Eventually, the analogs with methylamine substitution, 76-80, were synthesized via
condensation of the corresponding 3-formylindoles 18-22 with thiohydantoin,68 methylation of
intermediate thiones 66-70,69 followed by substitution of thioethers 71-75 with methylamine as
shown in Figure 2-7.

Compound
66, 71, 76
67, 72, 77
68, 73, 78
69, 74, 79
70, 75, 80

R1
4-Br
5-Br
6-Br
7-Br

Reagents and conditions: (a) ETA, EtOH, reflux, 1h; (b) CH3I, NaOH, MeOH, RT, 18h;
(c) CH3NH2, EtOH, sealed vessel, 70ºC, 24h.
Figure 2-7 The synthesis of 3′-N-methylamineaplysinopsin analogs (76-80).
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The general scheme for the synthesis of aplysinopsin analogs 31-65 is shown in Table
2-2. The condensation of 3-formylindoles with the appropriate imidazolidinones was carried out
according to the procedure from Djura and Faulkner.28 Briefly, equimolar amounts of the
appropriate indole aldehydes 18-22 and imidazolidinones 23-30 were mixed under nitrogen and
heated over an open flame until the reaction mixture began effervescing. Several minutes after
effervescence stopped, the mixture was cooled to room temperature. The crude mixture was
extracted with MeOH and insoluble materials filtered off. The solution was concentrated and
loaded on to silica gel for purification.
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Compd
18
19
20
21
22

R2 R3
H
H
H
H
H
H
H
H
H
H
Me H
Me H
Me H
Me H
Me H
H
H
H
H
H
H
H
H
H
H
Me Me
Me Me

Compd
23
24
25
26
27
28
29
30
R4
H
H
H
H
H
H
H
H
H
H
Me
Me
Me
Me
Me
H
H

R2
H
Me
H
H
Me
Me
H
Me

R3
H
H
Me
H
Me
H
Me
Me

R4
H
H
H
Me
H
Me
Me
Me

Compd R1 R2 R3 R4
5-Br Me Me H
48
6-Br Me Me H
49
7-Br Me Me H
50
Me H Me
51
4-Br Me H Me
52
5-Br Me H Me
53
6-Br Me H Me
54
7-Br Me H Me
55
H Me Me
56
4-Br H Me Me
57
5-Br H Me Me
58
6-Br H Me Me
59
7-Br H Me Me
60
Me Me Me
61
4-Br Me Me Me
62
5-Br Me Me Me
63
6-Br Me Me Me
64
7-Br Me Me Me
65
Table 2-2 Synthesis route to aplysinopsin analogs (31-65)

Compd
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

R1
4-Br
5-Br
6-Br
7-Br
4-Br
5-Br
6-Br
7-Br
4-Br
5-Br
6-Br
7-Br
4-Br

R1
4-Br
5-Br
6-Br
7-Br
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In vitro evaluation of library
Serotonin receptor affinity
A series of 50 synthesized compounds (31-80) were evaluated by the NIMH
Psychoactive Drug Screening Program (PDSP) at the University of North Carolina-Chapel Hill.
Briefly, compounds were first evaluated in a primary radioligand binding assay for 12 serotonin
receptor subtypes. A “hit” is defined as an inhibition > 50 % in the primary assay. Secondary
assays are used to determine the affinity constants (Ki) of hits at the specified serotonin receptor
subtypes. Ki’s are calculated using the Cheng-Prusoff equation.70
A cursory overview of the in vitro binding data reveals that the majority of the activity
among the 12 receptor subtypes lies in the 5-HT2 family, specifically at 5-HT2B and 5-HT2C.
Selected secondary binding highlights are shown in Table 2-3. Complete in vitro secondary assay
results for all compounds and receptors can be found in the supplementary material.
The library of compounds can be organized into eight groups of analogs based on the
substitution pattern of their imidazolidinone moiety. In each of those eight groups there are five
analogs, one non-brominated and four analogs brominated at positions 4, 5, 6, and 7 of the indole
ring. As shown in Table 2-3, the “A group”, with no N-methylations present on the
imidazolidinone moiety, showed the lowest Ki values, but with varying degrees of selectivity
among the 5-HT2 family of receptor subtypes. Compound 33 showed the highest affinity overall,
with a Ki = 35nM at 5-HT2C, however, it lacked selectivity among the 5-HT2 family.

The same

can be said for compounds 31 and 34, both of which possess nanomolar level affinities for 5HT2B and 5-HT2C, but were not notably selective for either one over the other.
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Cmpd

Structure

Binding affinity (Ki nM ± S.D.)
5-HT2A
5-HT2B
5-HT2C

31

1169 ± 158

232 ± 22

349 ± 44

33

58 ± 6

51 ± 7

35 ± 4

34

3128 ± 317

269 ± 34

201 ± 24

43

279 ± 21

94 ± 9

1271 ± 168

47

662 ± 92

99 ± 10

320 ± 61

Table 2-3 Selected serotonin receptor subtype binding affinities
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Methsergide
Ki = 26 nM
Compound 33
Ki = 51 nM
Compound 34
Ki = 262 nM

Chlorpromazine
Ki = 26 nM
Compound 33
Ki = 35 nM
Compound 34
Ki = 201 nM

Figure 2-8 Binding affinity graphs for compounds 33, 34, and positive controls towards 5HT2B and 5-HT2C receptors.
A general trend across all sub-groups of the library was that among each series of
compounds it was shown that brominated compounds possessed lower (or better) Ki values than
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their non-brominated counterparts. This was in line with previous reports that various
halogenations improved Ki values.38, 44 More specifically, we found that compounds brominated
at C-4 and C-5 possess higher binding affinities in general. This is intriguing as there have been
no reports of aplysinopsin analogs, synthetic or natural, halogenated at C-4. All of the naturally
occurring aplysinopsin derivatives are either halogenated at C-6 or are di-brominated at C-5 and
C-6. Concerning selectivity, across the entire library there was a noticeable selectivity for 5HT2B over 5-HT2C. The average relative selectivity index (SI) for 5-HT2B over 5-HT2C was 4.32.
A Ki value of 10,000 nM was assumed for compounds which were not tested in secondary
binding assays to determine the relative SI. As mentioned earlier, the previous aplysinopsin
SAR studies38, 44 examining 5-HT receptor activity have failed to evaluate binding affinity for the
5-HT2B receptor subtype, therefore it is difficult to make comparisons between the two data sets
based on selectivity among 5-HT2 receptor subtypes.
Concerning the effects of N-methylation of the imidazolidinone moiety, our results were
in contrast to previous reports that showed an importance of N-alkylation in selectivity among 5HT2 receptor subtypes.44 We did not observe a clear pattern of an increase in potency or
selectivity among serotonin receptor subtypes based on variation in N-methylation. In fact, our
most active compound subset was the group which had no alkylations of the imidazolidinone
moiety. Again, comparison to previous SAR studies38, 44 regarding imidazolidinone substitution
patterns is difficult, as they did not evaluate any analogs which were unsubstituted on the
imidazolidinone moiety.
MAO inhibitory activity
The 50 aplysinopsin analogs were also evaluated for their MAO-A and MAO-B
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inhibitory activities (see Table 2-4). In addition, clorgyline and deprenyl (Figure 2-9) were
evaluated as reference compounds. The results, expressed as IC50 and SI (selectivity index given
by the MAO B IC50 / MAO A IC50 ratio) values are summarized in Table 2-4. In general we
found that most aplysinopsin analogs showed greater inhibitory activity at MAO-A compared to
MAO-B, with IC50 values ranging from 0.0056-26.12 μM for MAO-A and 0.207-100 μM for
MAO-B. In particular, compound 54 displayed excellent MAO-A inhibitory activity, with an
IC50 value of 0.0056 μM and an SI of 80.24. It possesses a lower MAO-A IC50 than reference
compound clorgyline (0.0067 μM).

clorgyline

deprenyl

Figure 2-9 Reference compounds for MAO inhibitory assay
In general, we found that analogs which did not have N-methyl groups on the
imidazolidinone moiety displayed less inhibitory activity at both MAO-A and MAO-B,
indicating that N-methylation of the imidazolidinone moiety is important for MAO inhibitory
activity. Furthermore, mono-N-methylated compounds (36-45, 76-80) did not possess
significant activity at MAO-A or MAO-B. Advancing to di-N-methylated analogs (46-60),
revealed an overall increase in MAO inhibitory activity. The aforementioned 54 as well as 49
and 51, all displayed potent inhibition of MAO A with IC50 values of 0.0056 μM, 0.029 μM, and
0.035 μM respectively. Compounds 51 and 54 are identical in their N-methylation pattern on the
imidazolidinone, with positions N-2′ and N-4′ methylated, but differ in their indole bromination
pattern.
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MAO-A

MAO-B

MAO-A

MAO-B

IC50 (μM)

IC50 (μM)

IC50 (μM)

IC50 (μM)

31

12.750±0.250

57

5.475±0.125

26.833±1.041

4.9

32

11.49

58

3.250±0.563

16.767±0.751

5.16

11.333±0.289

1.93

59

1.123±0.587

25.733±1.537

22.91

3.683±0.448

25.333±1.041

6.88

60

1.080±0.364

4.260±0.177

3.94

35

5.517±0.511

27.800±0.721

5.04

61

0.098±0.024

9.017±0.076

92.32

36

12.167±0.764

43.167±3.055

3.55

62

0.623±0.153

5.217±0.257

8.37

37

26.167±1.756

>100

-

63

0.085±0.006

0.370±0.017

4.38

38

8.000±0.781

24.500±1.803

3.06

64

0.018±0.001

0.207±0.015

11.19

39

6.075±0.175

35.667±1.607

5.87

65

0.153±0.008

2.817±0.076

18.37

40

6.107±0.257

34.333±0.577

5.62

66

14.333 ± 0.577

24.333 ± 4.041

1.69

41

1.967±0.153

34.333±1.893

17.46

67

0.267 ± 0.029

0.450 ± 0.095

1.68

42

1.517±0.126

37.000±1.000

24.4

68

1.233 ± 0.252

2.567 ± 0.176

2.08

43

0.327±0.025

4.300±0.200

13.16

69

1.533 ± 0.153

2.567 ± 0.208

1.67

44

0.165±0.039

3.800±0.100

23.03

70

0.543 ± 0.038

1.237 ± 1.614

2.27

45

1.197±0.090

14.267±0.681

11.92

71

2.783 ± 0.202

59.333 ± 4.041

21.31

46

3.075±0.075

33.833±2.363

11

72

0.677 ± 0.050

3.733 ± 0.321

5.51

47

2.583±0.362

26.333±0.577

10.19

73

7.133 ± 0.321

8.750 ± 0.250

1.22

48

0.263±0.025

11.633±0.777

44.18

74

0.533 ± 0.035

1.417 ± 0.202

2.65

49

0.029±0.001

2.667±0.153

91.95

75

0.627 ± 0.843

2.433 ± 0.115

3.88

50

1.900±0.050

12.833±0.666

6.75

76

13.333 ± 1.422

6.000 ± 0.819

0.45

51

0.035±0.001

10.017±0.076

290.34

77

1.800 ± 0.173

7.033 ± 1.419

3.9

52

2.067±0.208

51.167±1.607

24.76

78

1.200 ± 0.265

2.000 ± 0.781

1.66

53

0.236±0.307

2.700±0.050

11.44

79

4.433 ± 0.231

20.700 ± 2.858

4.66

54

0.0056±0.0002

0.447±0.035

80.24

80

3.900 ± 0.794

26.000 ± 1.000

6.66

55

0.052±0.001

3.117±0.126

60.52

clorgyline

0.0067±0.002

-

56

5.817±0.535

30.467±0.896

5.24

deprenyl

-

0.045±0.01

SIa

Compound

33.000±2.000

2.59

2.467±0.208

28.333±0.577

33

5.867±0.551

34

Compound

SIa

a

The values are IC50s computed from dose response curves and are mean ± S.D. of at least triplicate
observations.
b
The relative selectivity for MAO-A is defined by the ratio of IC50 (MAO-B)/IC50 (MAO-A) for each
compound.

Table 2-4 Aplysinopsin analogs tested for inhibition (IC50) of human MAO-A and MAO-B
activities in vitro
All three (49, 51, 54) are di-N-methylated, with one of the N-methylations occurring at
N-2′, which appears to play a large role in activity, as similar di-N-methylated compounds 56-60,
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which are unsubstitiuted at N-2′, are significantly less active. All three of the aforementioned
compounds also possess a high SI, especially 51, which has an SI of 290.34.
The series of five tri-N-methylated analogs (61-65) yielded the two lowest MAO-B IC50
values in compounds 63 and 64 (0.370 μM and 0.207 μM respectively). These compounds
lacked selectivity though, with each possessing strong inhibitory activity towards MAO-A as
well.
Concerning the bromination pattern, we found that bromination at C-5 and C-6 resulted
in the lowering of IC50 values across all eight groups of analogs. This is not surprising
considering that most naturally occurring halogenated aplysinopsin analogs are brominated at
these positions,71 and this is in agreement with a recent SAR study of indole analogs which
revealed that substitution at C-5 lead to increased potency and selectivity for MAO-B.72
Bromination at C-6 appears to be especially crucial for MAO-A inhibition, as halogenation at
that position resulted in the lowest IC50 values for each group of compounds.
Another area of interest was the relationship between the geometry of the C-8-C-1′
double bond and MAO inhibitory activity. During synthesis of the analogs, the E or Z
configuration is determined by the presence, or lack thereof, of a substituent at N-2′.34a If N-2′ is
substituted with a methyl or bulkier group, the condensation will result in a double bond with
predominantly E configuration. If N-2′ is non-methylated, bearing either a hydrogen atom or a
lone pair, the major product will be Z-configured at the C-8-C-1′ double bond. This
stereochemical outcome is confirmed using 1H, 13C heteronuclear coupling constants between H8 and C-5′.34b The E isomer possesses a larger H-8, C-5′ heteronuclear coupling constant (9-11
Hz) compared to the Z isomer (4-5.5 Hz). It appears that an E configuration is important for
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MAO-A selectivity and potency. The aforementioned three most active groups (47-50, 51-55,
and 61-65) are all E configured due to their N-2′ methylation. Compounds 56-60, which are also
di-methylated, but Z configured, are significantly less active, insinuating that E configuration is
an important SAR factor.
MAO inhibitors, which are potent and selective in addition to reversible, are of special
interest to researchers. Thus, we evaluated three potent and selective analogs to assess their
pharmacokinetic binding profiles. Compound 54 was selected due to its potent and selective
MAO-A inhibition, and compounds 63 and 64 due to their being the most potent MAO-B
inhibitors we assayed. Notably, compounds 63 and 64 were also potent inhibitors of MAO-A.
Compound 54 inhibited MAO A through a reversible competitive mechanism with a Ki value in
the range of 13.5 to 18. 9 nM, while the analog 63 inhibited MAO A through a reversible mixedtype inhibition mechanism with a Ki value in the rage of 20.7 to 26.2 nM. All three compounds
tested inhibited MAO B through a reversible uncompetitive mechanism with Ki values in the
range of 0.185 to 1.648 uM.
An overview of both 5-HT and MAO in vitro data reveals that the most potent and
selective MAO-A inhibitors (51 and 54) did not possess significant affinities for any serotonin
receptor subtypes. Furthermore, we found that analogs with the lowest Ki values for serotonin
receptor subtypes (33, 43, and 47) did not possess significant MAO-A or MAO-B inhibitory
activity. This is important because acting on both targets could lead to issues such as serotonin
syndrome, as discussed in Chapter 1.
In vivo evaluation of lead compounds
The previous study assessing in vivo efficacy of aplysinopsins found that despite potent
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in vitro CNS activity, aplysinopsins displayed diminished or non-existent in vivo activity.45
Kochanowska et al. evaluated the parent compound aplysinopsin (51) in a Porsolt forced swim
test. It did not display any significant antidepressant activity. Based on these findings we sought
to evaluate our compounds in a different behavioral model. We chose the chick anxietydepression model. It is different from the aforementioned forced swim test in that it acts as both a
panic model to simulate anxiolytic conditions62 and as a behavioral despair model to evaluate a
depression-like state.73 Further, the model shows solid face,74 construct,75 and predictive
validity.75-76 The chick anxiety-depression model entails isolation of socially raised chicks
isolated at 5-6 days post-hatch. Chicks tested with conspecifics show low rates of vocalization
throughout the session whereas chicks tested in isolation show high rates of distress
vocalizations (DVocs) during the first 5 minutes (i.e., the anxiety-like phase; see ref 62) which
decline over the next 20 minutes by 40-50% of the initial rate and remain steady throughout the
remaining isolation period (i.e., depression-like phase). The reduced DVoc rates during this
latter phase mirror the pattern seen in traditional behavioral despair depression models.
In addition to using a new behavioral model, we assessed whether key structural changes
(e.g. halogenations and N-methylations) would result in increased in vivo efficacy profiles.
Based on our in vitro results, we chose three lead compounds (33, 51, 54) to be evaluated in the
in vivo anxiety-depression model.62 Compounds 51 and 54 showed nanomolar level affinity for
MAO-A and both had a high selectivity index for MAO-A over MAO-B.77 Despite its limited
selectivity among 5-HT2 receptor subtypes, compound 33 was chosen due to its potency and
ability to serve a good primary representative of the general aplysinopsin pharmacophore in
initial in vivo screening to assess bioavailability.
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CMPD 33
Notable Binding 5-HT Ki’s:
5-HT2A = 58 6 nM
5-HT2B = 51 7 nM
5-HT2C = 35 4 nM

CMPD 51
Notable MAO-A inhibitory
activity/selectivity:
IC50 = 35 1
SI MAO-B/MAO-A= 290.34

CMPD 54
Notable MAO-A inhibitory
activity/selectivity:
IC50 = 5.6 0.2
SI MAO-B/MAO-A= 80.24

Figure 2-10 Lead compounds selected for in vivo screening

Figure 2-11 Mean distress vocalizations as a rate/minute function (+/- SEM) for time in five
minute intervals.

Compounds were screened in the chick anxiety-depression model at 10, 30, and 100
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nM/kg concentrations. Of the three compounds tested, 33 displayed the most promising activity.
The pattern of distress vocalization rates across the isolation stressor for the various treatment
conditions are summarized in Figure 2-11 for compound 33. Socially tested chicks given vehicle
displayed few DVocs across the test session. Vehicle-isolated chicks exhibited high DVoc rates
during the first five minute block (anxiety-like phase) that declined over the next 25-30 minute
period to approximately 50% of the initial rate and remained relatively stable for the remaining
of the test session (depression-like phase). During the anxiety-like phase, none of the tested
compounds altered DVocs. Imipramine attenuated the decline in DVocs during the depressionlike phase (i.e., antidepressant effect). Further, the 30 nM/kg dose of 33 produced modest
attenuation of the depression-like phase. Consistent with these observations, a two-way ANOVA
revealed a significant drug treatment effect F(5,726)=23.44, p<0.0001, a significant isolation
time effect F(11,726)=35.43, p<0.0001, and a significant drug x isolation interaction
F(55,726)=2.05, p<0.0001.
These findings prompted an additional set of analyses to evaluate drug treatment effects
during the anxiety-like phase (0-5 m), the first half (30-45 m) of the depression-like phase, and
the second half (45-60 m) of the depression-like phase. These analyses for compound 33 are
summarized in Figure 2-12, Figure 2-13, and Figure 2-14. A one-way ANOVA of the DVoc
data from the anxiety-like phase (0-5 min block; see Figure 2-12) revealed a significant treatment
effect F(5,66)=32.86, p<0.0001. Fisher’s post-hoc analyses revealed that the mean DVoc rate of
the isolated-vehicle group was higher than mean DVoc rate of the social-vehicle group,
p<0.0001. All other relevant comparisons failed to reach statistical significance.
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Mean Distress Vocalizations

140
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*

100

80
60
40
20
0

Vehicle
Social

Vehicle
Isolated

Imipramine CMPD 33
5mg/kg
10 nM/kg

CMPD 33 CMPD 33
30 nM/kg 100 nM/kg

Treatment Group

Figure 2-12 The effects of social separation on mean DVocs (+/- SEM) in each drug
treatment condition under the anxiety-like phase (minutes 1-5).
A one-way ANOVA of the DVoc data from the first half of the depression-like phase
(see Figure 2-13) revealed a significant treatment effect F(5,66)=17.605, p<0.0001. Post-hoc
analyses (paired t-test) revealed that in the isolated-vehicle group the mean DVoc rate for the
depression-like phase was lower than in the anxiety-like phase, p<0.0001 and that Fisher’s least
significant differences (LSD) demonstrated imipramine attenuated this decline, p<0.0001. All
other relevant comparisons failed to reach statistical significance.
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Mean Distress Vocalizations
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*

60
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Vehicle
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Imipramine CMPD 33
5mg/kg
10 nM/kg
Treatment Group

CMPD 33 CMPD 33
30 nM/kg 100 nM/kg

Figure 2-13 The effects of social separation on mean DVocs (+/- SEM) in each drug
treatment condition under the first depression-like phase (minutes 31-45).
Analysis of the second half of the depression-like phase (see Figure 2-14) showed a
significant treatment effect F(5,66)=14.344, p<0.0001. A paired t-test revealed that in the
isolated-vehicle group the mean DVoc rate for the depression-like phase was lower than in the
anxiety-like phase, p<0.0001. Fisher’s LSD revealed that the mean DVoc rates of the
imipramine group (p=0.0002) and 30 nM/kg 33 (p=0.017) were higher than the mean DVoc rate
of the isolated-vehicle group.
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Figure 2-14 The effects of social separation on mean DVocs (+/- SEM) in each drug
treatment condition under the second depression-like phase (minutes 46-60).
Data from the in vivo screening demonstrated that isolation stress produced sequential
anxiety-like and depression-like phases and that the positive control imipramine produced
antidepressant effects in the model. A modest antidepressant effect was seen with compound 33
at the intermediate dose during the latter half of the depression phase. This late onset of action
may reflect the interaction of this compound at serotonin receptors and that an isolation test
session beyond the 60 minute may reveal more robust effects.74
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Conclusion and Discussion
In conclusion, we report the synthesis of 50 aplysinopsin analogs which were evaluated
for their affinity at 12 serotonin receptor subtypes and 34 other CNS receptors, in addition to
inhibitory activity of MAO isoforms A and B. Previous reports indicated that aplysinopsin
analogs possessed affinity and selectivity for serotonin receptor subtypes.38, 44 Both of these
reports pointed to key structural features that allowed analogs to have a high degree of selectivity
for 5-HT2C over 5-HT2A. Among those were C-6 halogenation. Both studies found that the
inclusion of a larger halogen (bromine or chlorine) at C-6 led to an increased binding affinity and
selectivity for 5-HT2C. If C-6 was substituted with a smaller halogen (fluorine) or left
unsubstituted, the molecules were selective for 5-HT2A. As mentioned previously, both of the
previous studies only evaluated affinity at those two receptor subtypes.
Bromination of the indole moiety increased aplysinopsins’ binding affinity for the 5-HT2
subfamily of receptors. More specifically, bromination at C-4 and C-5 increased affinity the
most. In general, analogs showed a selectivity for 5-HT2B over 5-HT2A and 5-HT2C. This
finding is important, as aplysinopsins have previously not been evaluated for their 5-HT2B
affinity, and increased affinity at this receptor can often lead to undesirable side effects. As more
information becomes available, such as the recent report of a 5-HT2B crystal structure with
ergotamine bound78, we should be able to better understand the binding behavior of 5-HT2B
selective ligands and design more selective ligands. In comparing our results to the previous
studies regarding selectivity between 5-HT2A and 5-HT2C, we also observed a general trend of
increased selectivity for 5-HT2C when C-6 was brominated compared to unsubstituted. The
previous report by Cummings et al.44 also noted that halogenation (of any type) at C-5 resulted in
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a lack of affinity for either receptor. Analogs with bromination at C-5 were actually some of the
most active and selective analogs in our library. Possible explanations for these conflicting
results could be differences in the assay and cell culture conditions.
The other area of modification was the substitution of the imidazolidinone moiety. Our
results showed no clear pattern regarding the effect of N-alkylation of the imidazolidinone
moiety as far as serotonin affinity and selectivity were concerned. In fact, we observed the most
potent affinities in the subgroup which had no N-alkylations of the imidazolidinone moiety.
Both of the previous studies found that alkylation of R2 and R4 were important for binding to
serotonin receptor subtypes 5-HT2A and 5-HT2C. However, neither of these studies evaluated
analogs which were unsubstituted on the imidazolidinone moiety, so comparison of data is not
possible.
Biological evaluation of the MAO-A and MAO-B inhibitory activities of these
compounds revealed some potent and selective MAO inhibitors. The most active compound 54,
which is brominated at C-6 and methylated at N-2′ and N-4′, showed strong inhibitory activity at
MAO-A (IC50 of 5.6 nM) and had an SI of 80.24. We found several factors important in
selectivity and potency. The first is multiple N-methylations of the imidazolidinone moiety, one
of which should be the methylation of N-2′, in addition to either N-3′ or N-4′. Secondly,
bromination at C-5 or C-6 is important for MAO-A potency and selectivity. These results
suggest that the aplysinopsin scaffold may be useful in designing selective MAO inhibitors.
Based on the in vitro screening findings, we chose to evaluate three compounds in an in
vivo model. Similarly to previous in vivo studies of aplysinopsins using different depression
models, we were unable to reproduce the in vitro efficacy in an animal model. However, one
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compound, 33, did exhibit a modest antidepressant effect in the later stages of the evaluation
period. It is clear that the aplysinopsin scaffold has potential to generate leads to treat CNS
disorders or serve as molecular probes to further investigate the underlying selectivity issues
among 5-HT receptor subtypes and MAO isoforms A and B.
Experimental
Chemistry
Unless specified all reagents were purchased from commercial sources and used without
further purification. Compounds were purified via column chromatography using Sorbtech
silica gel, 60A, 40-63um from Sorbent Technologies. Whatman silica gel F254 polyester backed
plates were used for TLC and visualized with UV light and/or ninhydrin, vanillin, and
anisaldehyde. NMR spectra were recorded on a 400 MHz Bruker instrument (400 UltraShield,
54 mm standard magnet bore, Billerica, MA) with 3mm direct carbon probe. 1H-NMR and 13CNMR spectra were recorded at 400 MHz and 100 MHz, respectively. Chemical shifts were
standardized to TMS and solvent signals. All biologically evaluated compounds were found to
possess ≥ 95% purity by HPLC (UV detection at 210 and 254 nm). Purified samples were
analyzed by LC-MS (Bruker Daltonik microTOF, Leipzig Germany) using a 150 x 4.6 mm C8
column (Luna Phenomenex). HR-ESI-MS analysis was done in positive ionization mode.
General procedures for the synthesis of aplysinopsin analogs and full characterizations of
three compounds evaluated in vivo are provided below. Analytical data for all other compounds
can be found in the Supplementary Data section.
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General procedure for the synthesis of aplysinopsin analogs 31-65 (GP1)
Equimolar amounts of the appropriate 3-formylindoles 18-22 and imidazolidinones 23-30
were mixed under N2 and heated over an open flame until the reaction mixture began
effervescing. Several minutes after the effervescence stopped, the mixture was cooled to room
temperature. The crude mixture was extracted with MeOH and insoluble materials filtered off.
The solution was concentrated and loaded on to silica gel for purification using.
General procedure for the synthesis of aplysinopsin analogs 66-70 (GP2)
Equimolar amounts of the appropriate 3-formylindoles 18-22 and thiohydantoin 4 were
dissolved in abs. EtOH and 1 mL of ethanolamine was added. The mixture was heated at reflux
for 1 h. After cooling the precipitate was filtered off and dried to yield compounds 66-70, which
were used without further purification.
General procedure for the synthesis of aplysinopsin analogs 71-75 (GP3)
To a solution of appropriate intermediates 66-70 (1.5 mmol) and NaOH (1.5 mmol) in 5
mL of MeOH and 0.5 mL H2O was added MeI (1.5 mmol). The mixture was stirred at room
temperature for 18h. The resulting precipitant was filtered and dried to yield compounds 71-75,
which were used without further purification.
General procedure for the synthesis of aplysinopsin analogs 76-80 (GP4)
Compounds 71-75 were dissolved in abs. EtOH and 2x molar equivalents of CH3NH2
was added. The mixture was heated to 70ºC in a sealed vessel for 24h. After cooling the crude
mixture was purified on silica gel.
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Figure 2-15 1H and 13C NMR spectra of compound 33.
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Figure 2-16 1H and 13C NMR spectra of compound 51.
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Figure 2-17 1H and 13C NMR of compound 54.
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(Z)-2-Amino-5-[(5-bromo-1H-indol-3-yl)methylene]-1H-imidazol-4(5H)-one (33)
5-Bromo-3-formylindole (448 mg, 2 mmol) and demethylcreatinine (198 mg, 2 mmol)
were reacted according to GP1 to yield 33 (380 mg, 62% yield). 1H NMR (400 MHz, DMSO) δ
12.44 (s, 1H), 8.41 (s, 1H), 8.16 (s, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.34 (d, J = 8.6 Hz, 1H), 7.19
(s, 1H). 13C NMR (101 MHz, DMSO) δ 164.06, 155.63, 135.08, 129.89, 129.14, 125.84, 121.64,
121.36, 114.63, 114.01, 109.09, 108.19. HRESMS m/z calcd 305.0038 (M.+ +H); found:
305.0040.
(E)-5-[(1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (51)
3-formylindole (290 mg, 2 mmol) and 1,3-dimethyl-2-imino-4-imidazolidinone (254 mg,
2 mmol) were reacted according to the above GP1 to yield 51 (365 mg, 72% yield). 1H NMR
(400 MHz, DMSO) δ 12.05 (s, 1H), 9.31 (s, 1H), 8.97 (d, J = 2.4 Hz, 1H), 8.07 (d, J = 7.4 Hz,
1H), 7.51 (d, J = 7.4 Hz, 1H), 7.30 (s, 1H), 7.28 – 7.18 (m, 2H), 3.50 (s, 3H), 3.19 (s, 3H).

13

C

NMR (101 MHz, DMSO) δ 160.53, 152.24, 136.22, 131.67, 128.14, 123.24, 122.25, 121.20,
118.95, 116.21, 112.80, 108.94, 29.30, 26.65. HRESMS m/z calcd 255.1246 (M.+ +H); found:
255.1290.
(E)-5-[(6-Bromo-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (54)
5-Bromo-3-formylindole (448 mg, 2 mmol) and 1,3-dimethyl-2-imino-4-imidazolidinone
(254 mg, 2 mmol) were reacted according to the above GP1 to yield 54 (312 mg, 47% yield). 1H
NMR (400 MHz, DMSO) δ 12.17 (s, 1H), 9.35 (s, 1H), 8.96 (s, 1H), 8.37 (s, 1H), 7.47 (d, J =
8.5 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.28 (s, 1H), 3.48 (s, 3H), 3.19 (s, 3H).

13

C NMR (101

MHz, DMSO) δ 160.56, 152.42, 134.96, 132.62, 130.02, 125.69, 122.81, 121.62, 115.65, 114.76,
114.15, 108.64, 29.37, 26.69. HRESMS m/z calcd 333.0351 (M.+ +H); found: 333.0352.
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Note: For physical data of all compounds tested, see Chapter 4.
Bioassays
In vitro evaluation of serotonin binding affinity
Ki determinations were generously provided by the National Institute of Mental Health's
Psychoactive Drug Screening Program. Briefly, compounds are initially evaluated in a primary
binding assay, in which they are tested at a final concentration of 10 μM. They are tested in
quadruplicate and compounds that show > 50% inhibition are deemed hits and advance to
secondary radioligand binding assays. Here compounds are tested at eleven concentrations (0.1,
0.3, 1, 3, 10, 30, 100, 300 nM, 1, 3, 10 μM) to determine the Ki values at specific receptors. For
complete experimental details please refer to the PDSP web site http://pdsp.med.unc.edu/ and
click on "Binding Assay" on the menu bar.
In vitro evaluation of MAO inhibitory activity
An in vitro assay was designed to measure the effect of aplysinopsin analogs on MAO-A
and B activity. Recombinant human MAO-A and B were obtained from BD Biosciences
(Bedford, MA, USA). Kynuramine bromide, 4-hydroxyquinoline, clorgyline and R-(-)-deprenyl
were purchased from Sigma (St Louis, MO, USA). Aplysinopsin analogs (10-9 to 10-2M),
clorgyline and deprenyl (10-12 to 10-5M) were tested for inhibition of human MAO-A and B
activity. MAO-activity was assessed by a modification of the fluorometric method of Kralj79 and
was adopted for 96 well plate’s format. The 200 µL reaction mixtures containing recombinant
human MAO-A or MAO-B (5 µg/mL) and the test compounds in KH2PO4 buffer (100 mM; pH
7.4) were pre-incubated at 37oC for 15 min. The reactions with positive control wells with
standard MAO inhibitors and controls without inhibitors were also set up simultaneously. The
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reaction was initiated by addition of kynuramine (250 µM) in potassium KH2PO4 (100 mM; pH
7.4) and incubated further at 37oC for 20 min. After incubation the reaction was stopped by the
addition of 75 µL of 2N NaOH. The deaminated product of kynuramine, which spontaneously
cyclizes to 4-hydroxyquinoline, was determined fluorometrically at 320 nm excitation and 460
nm emission wavelengths in a plate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA,
USA). Wells receiving no test compounds were used as controls to calculate the inhibition
percentage. The IC50 values were computed from the dose response inhibition curves prepared
by GraphPad.
In vivo evaluation of aplysinopsin analogs
All procedures involving animals were performed as approved by the Institutional
Animal Care and Use Committee of The University of Mississippi. Cockerels (Production Red,
Ideal Poultry, Cameron, TX, USA) were received into the laboratory at 2 days post hatch and
housed in 34 x 57 x 40 cm cages with 12 chicks per cage. Food and water are available ad
libitium via gravity feeders. Daily maintenance that entails the replacement of tray liners and
filling food and water gravity feeders is conducted during the hour that precedes the animal’s
dark cycle. Lights are operated on a 12:12 light dark cycle. Supplemental heating sources are
provided to maintain appropriate housing temperatures in the range of 32 +/- 1oC.
Testing equipment
A six unit testing apparatus containing Plexiglas chambers (25 x 25 x 22 cm) surrounded
by sound attenuating media is used to record separation-induced vocalizations. Each unit is lined
with acoustical fiber media, illuminated by a 25-W light bulb, and ventilated by an 8-cmdiameter rotary fan (Model FP-108AX S1, Commonwealth Industrial Corp., Taipei, Taiwan).
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Miniature video cameras (Model PC60XP, SuperCircuits, Inc., Liberty Hill, TX) mounted in the
sound-attenuating enclosures at floor level and routed through a multiplexor (Model PC47MC,
SuperCircuits, Inc.) provided televised display of the chicks for behavioral observation. To
record DVocs, microphones (Radio Shack Omnidirectional Model 33-3013 modified for AC
current) are mounted at the top of the Plexiglas chamber. These vocalizations are routed to a
computer equipped with custom designed software for data collection.
Methods
Squads of six chicks were taken from their home cage and placed within a lidded plastic
transport container. To track subject assignment to treatment conditions, chicks are marked
using colored felt pens and body weight is determined for each chick to determine dosing and
identify outliers (i.e., low body weight). Drugs were administered IP 15 minutes prior to
behavioral testing. Chicks were placed into individual testing units for a 60 minute session.
Following the completion of the session chicks were removed from the testing apparatus and
returned to their home cage.
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CHAPTER 3
DESIGN OF A SECOND GENERATION OF APLYSINOPSIN ANALOGS WITH
IMPROVED IN VIVO EFFICACY
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3. Introduction
Our previous results showed that the aplysinopsin scaffold has potential to yield drug
leads which have neuromodulatory activities. The previous results also showed that future drug
design efforts would need to focus on improving the in vivo efficacy as well as maintaining
serotonin receptor affinity and MAO inhibitory activities. We were able to identify lead
compounds which possessed nanomolar level affinities for 5-HT receptor subtypes and MAO
isoforms A and B. However, the lack of in vivo efficacy indicates that the compounds are not
reaching the target tissue, in this case the brain, with a high enough plasma concentration to elicit
significant effects. There are a number of possible reasons for the loss of efficacy from cell based
assays to an animal model. Most pharmaceutical companies have entire divisions devoted to
solving these issues and improving the in vivo efficacy of lead compounds. As medicinal
chemists continue to explore new chemical space in terms of lipophilicity and solubility, there is
a constant push to find ways to improve bioavailability, especially as it pertains to CNS drugs.
Poor bioavailability is one of the leading causes of drug failure in pre-clinical and clinical
development.80 This lack of bioavailability can generally be traced back to the relationship
between physiochemical properties (e.g. logP, MW, PSA, etc) and the ADME (absorption,
distribution, metabolism, and excretion) characteristics of lead compounds. There are numerous
reviews about the physiochemical properties associated with successful CNS-active drugs.81 Out
of those, several guidelines, or “rules” have emerged as standards for evaluating the likeliness of
a drug to cross the Blood-Brain Barrier (BBB) and be CNS-active. First and foremost is
Lipinski’s “Rule of Five,” which asserts that if all five of the following conditions are met, then a
drug is likely to have good bioavailability:82
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Molecular weight ≤ 500
LogP is ≤ 5
Hydrogen bond donors ≤ 5 (sum of OHs and NHs)
Hydrogen bond acceptors ≤ 10 (sum of Ns and Os)
Number of rotatable bonds ≤ 10

Lipinski’s rules have been validated by numerous studies to be accurate and useful for
predicting a drug’s bioavailability.83 Several years after his initial proposal of the “Rule of
Five,” Lipinski put forth an additional, more constrictive set of rules specifically for CNS
penetration.84 As discussed earlier, drugs which must penetrate the CNS have a narrower
window of physical properties. Lipinski proposed that CNS penetration is likely if the following
parameters are met:





Molecular weight ≤ 400
LogP ≤ 5
Hydrogen bond donors ≤ 3
Hydrogen bond acceptors ≤ 7

Another set of similar rules are those of Clark,85 who proposed that potential CNS drugs should
meet the following criteria:






N+O<6
Polar surface area < 60-70 Å2
MW < 450
Log D = 1-3
ClogP – (N + O) > 0

Clark’s rules bear some similarity to Lipinski’s rules. There are also numerous other sets of
“rules” or guidelines to follow when designing a library of drug leads. The key for greatly
adopted use of these guidelines is their ease of use. For the most part, medicinal chemists are
able to quickly tabulate these properties and use the results to aid in compound library design.
When looking at the various parameters that contribute to the ADME profile, we wanted
59

to evaluate which parameters might be diminishing the in vivo efficacy of our aplysinopsin
analogs. For a CNS drug to cross the BBB and reach its therapeutic target, there are several
obstacles that must be overcome. First is avoiding excessive metabolism. We made use of an in
vitro stability study and metabolism profiling assay to assess the metabolism of aplysinopsin
analogs. If a drug is excessively metabolized before it reaches the BBB, it will likely not be
active. Second is permeability once it reaches the BBB. The BBB is a major detriment to CNS
drug development. There are essentially three ways that drugs can cross the BBB: passive
paraceullar diffusion, passive transcellular diffusion, and active transport (influx and efflux).
Paracellular diffusion is uncommon due to the epithelial cells which form tight junctions in the
BBB. Due to this, the most common way for drugs to diffuse across the BBB is transcelluar
diffusion. There are currently a variety of in vitro, in vivo, and in silico methods used to
investigate BBB permeability of drug candidates.86 An in silico (QikProp by Schrödinger)
method was used to evaluate several predicted permeability parameters. Last, but not least, is
the ability of efflux pumps to pump out compounds which are able to successfully cross the
BBB. The multidrug-resistance transporter (MDR-1), also known as P-glycoprotein, is the most
widely studied of the efflux pumps. MDR-1 is found ubiquitously through the body, not just in
the BBB. Many drugs have been found to be substrates of MDR-1, and it plays an important
role in the development of CNS drug candidates. An in vitro MDR-1 assay was used to assess
whether aplysinopsins were subjected to MDR-1 transport, which could explain their lack of in
vivo efficacy.
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Design of Second Library of Aplysinopsin Analogs
Poor ADMET properties account for the failure of nearly 40% of drug candidates in
clinical trials.87 Being able to predict these failures earlier can help save time, money, and
resources. Current technology allows us to predict these properties quickly and accurately
without using costly and time consuming methods such as high-throughput screening. Using
programs such as QikProp by Schrodinger, we can evaluate not only classic ADME parameters
like Lipinki’s “Rule of Five,” but also other pharmaceutically relevant properties such as polar
surface area (PSA), log S (solubility in water), log P (partition in octanol/water mixture), log BB
(blood-brain partition coefficient), Caco-2 and MDCK cell permeabilities, and TSW (toxicity
structural warnings). QikProp is able to compute these pharmaceutically relevant properites with
high degrees of precision, as shown in Figure 3-1, where the QikProp predicted water/octanol
partition coefficients are compared to the experimental values. They were found to be in
excellent agreement with an R2 value of 0.92. Similar R2 results were found for all QikProp
predicted properties. QikProp can perform calculations rapidly, analyzing thousands of
compounds in very short periods of time depending on computing power available.
When building a virtual library of aplysinopsin compounds to analyze using QikProp, we
had to consider which areas of the aplysinopsin scaffold are available to be modified. In general,
they can be classified into three groups: 1) substitution of the indole ring, 2) substitution at the
indole nitrogen, 3) alterations of the substitution pattern on the imidazolidinone moiety (see
Figure 3-2).
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Figure used with permission from Schrodinger.
Figure 3-1 QikProp-predicted water/octanol partition coefficients plotted against
experimental values.

Figure 3-2 Possible sites of modification of aplysinopsins scaffold.
Because we are only looking at a limited amount of chemical space (only the aplysinopsin
scaffold), we are unlikely to see a great deal of variation in any one individual parameter.
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However, we can still observe measurable changes in the physicochemical properties analyzed.
Thus, we can see which structural changes might lead to improvements in the overall ADME
profile of the compounds.
We screened a library of over 400 aplysinopsin analogs with modifications at the
aforementioned positions, using known modifications to triptamines, indoles, and other CNS
alkaloid drugs. One drawback to these in silico programs is that they generate a wealth of data
which is often hard for medicinal chemists to interpret. For this reason, we chose to focus on a
set of properties and predictors which could give us clear information to guide the construction
of our new library. The properties we chose to focus on, as well as a brief description of each,
are listed below in Table 3-1. We were especially interested in the various permeability
predictors (QPPMDCK, QPlogBB). As in vitro and in vivo models of BBB permeability are
cost prohibitive to run in a HTS manner for most academic groups, we relied on the predicted
values from QikProp to guide us in terms of permeability measurements. In addition, we were
also interested in the ability to predict toxicity issues, such as the blockage of HERG (human
ether-a-go-go-related) K+ channels. Drugs which interfere with this voltage-gated K+ channel
can cause potentially fatal cardiac side effects, including TpD. This has led to several drugs
being pulled off the market, such as the antipsychotic sertindole.88 Also, HERG blockage is a
major cause of drug development delays, delays in approval, and in some cases removal from the
market or black box warnings.89 Patch-clamp assays to measure HERG blockage are complex
and expensive,90 therefore accurate in silico methods to predict possible HERG interference are
quite useful.
Another interesting pharmacokinetic parameter evaluated was the rate of protein binding.
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Excessive binding to human serum albumin (HSA) can lead to drug safety issues, and more
importantly in our case, decreased brain penetration.91 Since only free/unbound drug is able to
passively diffuse across the BBB, a higher rate of HSA binding by a drug reduces the
concentration of free drug available to cross the BBB. Evaluation of the QPlogKhsa values
could give us valuable insight into possible causes of the lack of brain penetration.
Property of Descriptor
#stars

CNS
QPlogHERG
QPPCaco
OPlogBB
QPPMDCK

QPlogKhsa
RuleOfFive

Description

Range/Recommended
Values

Number of property or
descriptor values that fall
outside the 95% range of similar
values for known drugs. A large
0-5
number of stars indicates that a
drug is less drug-like that
molecules with fewer start.
Predicted CNS activity on a -2
-2 - +2
(inactive) to +2 (active) scale.
Predicted IC50 value for the
blockage of HERG K+
Concern below -5
channels.
Predicted Caco-2 cell
permeability. Caco-2 cells are a
<25 poor, >500 great
model for the gut-blood barrier.
Predicted brain/blood partition
-3.0 – 1.2
coefficient.
Predicted apparent MDCK cell
permeability. MDCK cells are
<25 poor, >500 great
considered a good mimic for the
blood-brain barrier.
Prediction of binding to human
-1.5 – 1.5
serum albumin.
Number of violations of
Maximum is 5.
Lipinski’s rule of five.
Table 3-1 QikProp properties and descriptors.

64

QikProp analysis results
Initially we considered the overall predicted CNS activity, which QikProp evaluates on a
-2 to +2 scale. This value is calculated by compiling multiple other calculated properties and
evaluating them against a test set of known CNS compounds and their physicochemical
properties. The higher the number the better, thus a result of +2 would equate to a drug that had
a high probability of being CNS active, and -2 would be a drug that was not likely CNS active.
Our best predicted value was a 0. The range was 0 to -2. This was not surprising as the polar
nature of the aplysinopsin scaffold makes it an unlikely candidate to cross the BBB and be CNS
active, as we observed with our first set of lead compounds in in vivo studies. However, we used
these values as a tool to exclude some compound for further consideration. Going forward we
focused on compounds with a CNS values of 0 or -1. For clarity, each property or descriptor
discussed will now be done based on the area of the aplysinopsin which is modified as show in
Figure 3-2, with group 1 being those substituted on the indole moiety, group 2 those substituted
on the indole nitrogen, and group 3 being modifications of the substitution pattern on the
imidazolidinone ring.
It should be noted that we observed little change in the overall properties with any of the
substitutions made to the imidazolidinone ring. In fact, the highest/best values were when the
imidazolidinone was dimethylated, as in compound 28. For ease of discussion, it should be
assumed that unless noted otherwise, all compounds are alkylated at R2 and R4.
Next, we examined several permeability factors. We were most interested in those
permeability measurements that concerned CNS activity: QPlogBB and QPPMDCK. QPlogBB
is a measure of the predicted blood/brain partition coefficient, so the larger the number the better
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chance that the drug would have a higher concentration in the brain vs. the blood. The
QPPMDCK is the predicted MDCK cell permeability. MDCK (Madin-Darby canine kidney)
cells are widely used as models for the cerebral endothelial cells that make up the BBB due to
their similar cell structures, which includes tight junctions.92
For QPPMDCK, we observed a range of values from 6.842 all the way to 7687.354.
QikProp defines a score of <25 as being poor and >500 as being good. The 7687.354 value was
an outlier, as most of our values were in the range of 200-1500, with our statistical average being
a value of 944. In terms of group 1 modifications (those made to the indole ring), we observed
that the addition of polar groups (for example hydroxy groups) resulted in a drastic decrease in
QPPMDCK values. This should not be surprising, as the endogenous ligand serotonin, with its
5-hydroxy group, is not able to cross the BBB itself. The two best QPPMDCK values for group
1 compounds were from the 5-methoxyaplysinopsin analog (89) which had a QPPMDCK value
of 563.564, and 5-fluoroaplysinopsin analog (88), with QPPMDCK value of 967.232. Compared
to other halogen substituted analogs, the fluoro-substituted analog had the best QPPMDCK
value, perhaps due to its smaller size compared to other halogens, thus reducing the overall bulk
of the molecule.
Examining the QPPMDCK values for group 2 analogs (those substituted at the indole
nitrogen), the best values were observed for the N-benzylaplysinopsin analogs (81-85). On
average, these five analogs had a QPPMDCK value of 1829. The highest values were found
with the para-chloro-N-benzyl analog (2637) and the para-nitro-N-benzyl analog (1938).
Looking at similarly substituted analogs, the N-phenyl substituted analogs had substantially
lower values. For example, the para-cyano-N-phenyl analog had a QPPMDCK value of 189.
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Other groups examined included chloromethyl and chloroethyl substituted analogs, as well as
methylamino analogs. All of these exhibited lower QPPMDCK values than the N-benzyl
analogs.
Next we examined the QPlogBB values, which are representative of the steady state
distribution of a compound between the brain tissue and plasma. We found an average value of
-0.7969. It is somewhat difficult to discuss negative values being “positive,” however,
compounds with great BBB penetration profiles often have negative logBB values, for example
the logBB value of caffeine is -0.219. With that in mind, we examined compounds with values >
-1. Using that number as a threshold we essentially cut our library in half. The range of values
was from -2.453 to 0.086, with an average of -0.7969.
Looking at group 1 substations (on the indole moiety), we observed some of the lowest
values. Similar to the QPPMDCK values, addition of polar groups to the indole moiety
drastically lowers the QPlogBB values. In general, all of the proposed new analogs substituted
on the indole moiety scored relatively low compared to other analogs. We did observe that some
of our higher values obtained for this value were done with analogs from the first library of
compounds (30-80), suggesting that the halogenation of the indole moiety can improve this
QPlogBB value.
In regards to substitutions at the nitrogen atom of the indole, many of the same trends for
QPlogBB values were observed as with the QPPMDCK values. The N-benzyl series of analogs
provided some of the highest values, with para-chloro-N- benzyl scoring -0.281, a value similar
to that of the aforementioned caffeine. The N-methylaplysinopsin analog also scored well, with
a QPlogBB value of -0.299. We observed a limited SAR of this type of substitution, with a
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decreased QPlogBB value as the N-alkyl chain was lengthened to N-ethyl (-0.371) and N-propyl
(-0.452).
As mentioned previously, our primary motivation for using this ADME calculator was to
be able to assess permeability issues while using a rational approach in the design of our next
series of compounds. After reviewing the data generated by QikProp a “short list” of 50
compounds was assembled based on positive permeability data. Beyond the permeability data,
we were also looking at several other properties. First, were the basic Rule of Five properties as
discussed earlier. We did not observe frequent violations of these five rules, likely due to the
fact that while designing possible compounds for the QikProp assay, we did not propose
molecules that had blatant violations of any of the rules. However, there were a few proposed
structures that violated at least one rule. In most cases, this was due to a molecular weight over
500 or a LogP > 5.
We were also interested in examining the potential for excessive HSA binding, which can
lead to dramatic decreases in the amount of free/unbound drug in circulation. QPlogKhsa values
for our library ranged from -0.688 to 0.884, with an average of 0.447. For reference, it is useful
to know that many antidepressants used in the clinic today have relatively higher logKhsa values,
for example imipramine has a logKhsa of 0.75. The antidepressants triflupromazine and
chlorpromazine have logKhsa values of 1.05 and 1.1, respectively. Looking at the groups that
had positive permeability values, the previously discussed N-benzyl analogs had similar values
to those of the current antidepressant drugs, with an average of 0.7994 among that subset of
proposed analogs. The lowest values were for analogs which had polar substituents on the indole
ring (e.g. –OH) and halogenation at all positions (4, 5, 6, 7) of the indole ring as well.
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Concerning the predicted HERG K+ channel blockage IC50 values, we found a very small
variation in values across all compounds examined. The entire library of compounds only
covered the range of -6.004 to -4.26, with an average of -4.9787. QikProp notes that a
QPlogHERG below -5 should be a concern. As mentioned previously, HERG K+ blockage by
the pharmaceutical sertindole caused Long QT syndrome, a heart rhythm disorder that results in
fast, chaotic heartbeats. These side effects have prevented it from being approved by the FDA in
the US. Based on the structural similarity between sertindole and the aplysinopsin scaffold,
values at or below -5 are not surprising. If the aplysinopsin scaffold should advance further in
clinical development these concerns would definitely need to be further evaluated and addressed
properly.
Considering all of the above data, the synthetic feasibility of each potential group of
analogs was assessed. Based on that data, three groups of analogs were selected for synthesis in
order to further evaluate in in vitro and in vivo assay systems. These 12 compounds are shown
in Figure 3-3. The highlighted QikProp values for each of the proposed analogs are shown in
Table 3-2.
CMPD CNS
MW
QPlogHERG QPPCaco QPlogBB QPPMDCK QPlogKhsa RuleOfFive
0
344.415
-6.011
2030.987
-0.442
1064.008
0.715
0
81
0
378.86
-5.938
2038.425
-0.281
2637.092
0.833
1
82
0
378.86
-6.08
1786.328
-0.409
1635.765
0.817
0
83
0
389.4073
-5.419
2131.378
-0.301
1938.391
0.821
0
84
0
289.4073
-5.252
2045.582
-0.354
1872.032
0.811
0
85
0
279.2966
-4.83
940.391
-0.62
639.294
0.141
0
86
-1
296.328
-4.951
706.915
-0.751
340.043
-0.21
0
87
0
272.281
-4.668
1074.116
-0.417
967.232
0.034
0
88
0
284.317
-4.628
1128.129
-0.575
563.564
0.016
0
89
0
268.318
-4.859
1949.152
-0.299
1017.745
0.204
0
90
0
282.344
-4.954
1963.825
-0.371
1026.029
0.306
0
91
0
296.371
-5.171
1972.863
-0.452
1031.133
0.423
0
92

Table 3-2 Selected QikProp values for compounds 81-92
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H

H
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H
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p-Cl
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H
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H
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H
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H
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H
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H

o-NO2
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H
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CN

H

92

H
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Figure 3-3 Structures of proposed new library of aplysinopsin analogs
Metabolic stability of aplysinopsins
While concurrently evaluating a new library of analogs in the QikProp ADME prediction
program, we also assessed the in vitro metabolic stability of aplysinopsins. Compound 53 was
evaluated in an in vitro stability study and metabolism profiling assay. Metabolism greatly
influences the bioavailability of a drug. Rapid metabolism is a common cause of failure of a
drug to reach sufficient concentrations at the target tissue. Metabolism can be divided into two
phases: phase I and phase II. For this study, focus will be on phase I, where drugs are subjected
to oxidation by the CYP superfamily of enzymes. These enzymes are responsible for the
metabolism of the majority of marketed drugs.93 Liver microsomes (in our case, rat microsomes)
are commonly used to evaluate phase I metabolism. Using this in vitro system, intrinsic hepatic
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clearance (CLint) and metabolic half-life (T1/2) were determined. In addition, any major
metabolites produced are able to be evaluated. This may give direction in terms of telling which
part of the structure is undergoing metabolism, therefore we can make structural modifications to
reduce the susceptibility of a compound to metabolic turn-over if necessary.
Results of microsomal stability study
To determine the intrinsic rate of clearance (CLint) and metabolic half-life (T1/2),
compound 53 was incubated with rat liver microsomes with appropriate cofactors (NADPH), and
the level of the parent compound remaining was monitored at multiple time points. The results
for CLint and T1/2 are shown below in Figure 3-4. In general a CLint of <40 μL/min/mg is
considered ideal.94 Compound 53’s rate of clearance of 23 μL/min/mg is well below that
threshold. Concerning half-life values, our T1/2 value of 61 minutes is good, as the longer the
half-life the better. Compound 53’s T1/2 is comparable to that of imipramine (66 minutes), which
is used as the control in the chick/anxiety depression model we use to evaluate our compounds.
In addition, diazepam, which is used to treat anxiety and panic attacks, has a T1/2 of 54 minutes.
Thus, there is nothing about the observed CLint or T1/2 values that would indicate that microsomal
stability problems are the cause of aplysinopsins’ poor bioavailability. Despite compound 53’s
extended T1/2 there was one primary metabolite detected during GC/MS analysis using
Metabolynx software from Waters. The metabolite, with MW difference of +16, was determined
to be the result of an oxidation of the indole ring. See Figure 3-5.

71

Figure 3-4 Evaluation of the microsomal stability of compound 53
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Figure 3-5 Metabolite structural hypothesis
Synthesis of second generation aplysinopsin analogs
Following analysis of results obtained with QikProp and evaluation of the metabolism of
aplysinopsins, that data was used to select a new library of analogs to synthesize. The library
can be sub-divided into three basic groups: N-benzyl analogs (81-85), analogs which are
substituted on the indole moiety (86, 88, and 89), and analogs which are substituted on the
nitrogen of the indole moiety (87, 90-92). The general strategy for the synthesis is similar to the
previous work, with the synthesis of the 3-formylindole with the appropriate substitution first.
This is then followed by condensation of the 3-formylindoles with the imidazolidinone 28.
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Synthesis of N-benzyl analogs (81-85)
Initial efforts towards the synthesis of the N-benzyl aplysinopsin analogs focused on the
use of phase-transfer catalytic (PTC) conditions to introduce the benzyl group to 3-formylindole,
followed by the use of microwave irradiation for the condensation step (see Figure 3-6 and
Figure 3-7).95 The catalyst used was triethyl benzyl ammonium chloride (TEBA). Using this
method the N-benzyl-3-formylindoles were obtained in moderate yields (~50%), which was
much lower than the previously reported 90% yields using this methodology. Furthermore, the
use of microwave irradiation for the condensation of N-benzyl-3-formylindoles with
imidazolidinone 28 was much less efficient than previous methods used for the condensation
reaction. Considering these lower yields, an alternative approach for the synthesis of the Nbenzyl analogs was sought. A report from Ottoni et al. suggested that the N-benzyl-3formylindoles could be obtained in high (>90%) yields and in short reaction times with facile
workup conditions.96 This method uses a mild base (NaOH) and treatment of 3-formylindole
with the appropriate benzyl bromide in acetone. Upon addition of the benzyl bromide, a
precipitate forms almost immediately, which is filtered off and the solution concentrated to yield
the targeted N-benzyl-3-formylindoles, which can be used without further purification.

Figure 3-6 Synthesis of N-benzyl-3-formylindole intermediates
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As mentioned, the microwave irradiation method for the condensation was quite
inefficient, with yields lower than 30%. Using the previous condensation method of Djura and
Faulkner also produced low yields and significant decomposition of the N-benzyl starting
materials. Following this, several acid and base catalyzed condensation conditions were utilized,
all with equally low yields. The method of Boyd and Sperry,97 which used ethylene glycol as the
solvent (see Figure 3-7), was successful in produced a high yield condensation step. Their report
also cites high rates of decomposition of starting materials, which they suggest is due to the
instability of the starting material to the presence of acid or base at high temperatures. In seeking
a neutral reaction solvent, ethylene glycol was used and led to a successful condensation
reaction. Using the same solvent system produced the targeted products in moderate yields
(~70%).
Compound

R

81

H

82

p-Cl

83

o-Cl

84

p-NO2

85

o-NO2

Figure 3-7 Condensation of N-benzylaplysinopsin analogs 81-85
Synthesis of analogs substituted on the indole moiety
Compounds 86, 88, and 89 were synthesized using commercially available appropriately
substituted 3-formylindoles (see Figure 3-8). Using the method of Djura and Faulkner28,
condensation was carried out between the 3-formylindoles and the imidazolidinone 28 to yield
the desired target substituted aplysinopsin analogs.
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Compound

R

86

5-CN

88

5-F

89

5-OMe

Figure 3-8 Synthesis of compounds 86, 88, and 89
Synthesis of analogs substituted at the indole nitrogen
Compounds 90-92 were synthesized via alkylation of the nitrogen of the indole, using the
appropriate alkyl iodides in DMSO (see Figure 3-9). The N-substituted 3-formylindole
intermediates were obtained in the crystalline form and then subjected to the condensation
conditions, making use of ethylene glycol as the solvent. Compound 87, the N-acetyl
aplysinopsin analog, was prepared using commercially available N-acetyl-3-formylindole, which
was then subjected to condensation conditions.

Compound

R

87

-COCH3

90

-CH3

91

-CH2CH3

92

-CH2CH2CH3

Figure 3-9 Synthesis of compounds 87 and 90-92.
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In vitro serotonin receptor binding
The series of new analogs (81-92) were evaluated in the NIMH PDSP at UNC-Chapel
Hill. They were evaluated for their serotonin receptor affinity, as well as their affinity for 34
other CNS receptors (see Table 2-1). As before, they were initially evaluated in a primary radio
ligand binding assay, and hits which possessed inhibition > 50% in the primary assay were
evaluated in a secondary assay to determine their Ki values. A summary of these results is
shown below in Table 3-3.
Cmpd

Binding affinity (Ki nM ± S.D.)
5-HT2B
5-HT2C
5-HT3

5-HT2A
KOR
1,282
3,849
81
900
539
384
82
787
493
247
932
83
1,067
344
666
84
2,058
85
86
87
1,195
88
2,405
89
90
7,883
1,782
1,632
91
3,272
92
Table 3-3 Selected CNS receptor in vitro binding affinities for compounds 81-92.
Compounds 81 through 85 represent the N-benzylaplysinopsin derivatives. Most of the
activity was contained in this group of five analogs. Moderate activity at serotonin receptor
subtypes 5-HT2B and 5-HT2C was observed. These analogs, however, did not possess the in vitro
potency of the leads from the first library (see Table 2-3). The most active compound in terms of
5-HT2 affinity, was compound 83, the N-ortho-chlorobenzyl-aplysinopsin analog. It showed
moderate affinity for both 5-HT2B (787 nM) and 5-HT2C (247 nM). (See Figure 3-10)
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83

83

Figure 3-10 Binding affinity graphs for compound 83 positive controls towards 5-HT2B and
5-HT2C receptors.
An interesting note is the activity of these compounds at the 5-HT3 receptor, as well as
the κ-opioid receptor. The activity at 5-HT3 is especially interesting, as aplysinopsins have never
been reported to possess activity at this serotonin receptor subtype. Furthermore, unlike all of
the other serotonin receptor subtypes which are G-protein coupled receptors, 5-HT3 is a ligandgated ion channel receptor. The 5-HT3 receptor subtype, like other serotonin subtypes, has been
implicated in multiple CNS disorders.98 However, it has also received significant attention from
the pharmaceutical industry due to the ability of 5-HT3 antagonists to suppress chemotherapyand radiotherapy-induced vomiting.99 Three of the N-benzyl analogs showed nanomolar level
affinity for the 5-HT3 receptor subtype, with the two most potent being compound 83: ortho-Cl
(247 nM) and compound 84: para-NO2 (344 nM). See Figure 3-11.
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83

84

Figure 3-11 Binding affinity graphs for compounds 83, 84, and positive controls towards
5-HT3.
This is also the first report of aplysinopsins possessing affinity for the kappa opioid
receptor (KOR). The KOR system has drawn considerable attention from researchers who are
interested in its possible analgesic properties. Furthermore, researchers are especially interested
in possible opioid receptor ligands which may have better side effect profiles than the mu opioid
receptor agonists, such as morphine. Previous efforts to use KOR agonists as analgesics have
been slowed by their side effect profiles, which often includes sedation and dysphoria. Recently,
research has shifted its focus on possibly targeting the KOR in the peripheral nervous system,
with a view of avoiding some of these unwanted side effects.100 In a recent report, Bruchas et al.
describe how the kappa opioid receptor system may be implicated in regulating the serotonin
system in the brain via p38 mitogen-activated protein kinase (p38 MAPK).101 Compounds 82-84
showed nanomolar level affinity for the κ-opioid receptor (see Figure 3-12). It is important to
note that none of these compounds showed significant affinity for any of the other opioid
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receptor subtypes.
84

82

Figure 3-12 Binding affinity graphs for compounds 82, 84, and positive controls towards
KOR.
In vitro inhibition of MAO isoforms A and B
Compounds 81-92 were also evaluated for their MAO-A and MAO-B inhibitory
activities (see Table 3-4). Compared to the first library of compounds analyzed (see Table 2-4),
less potent overall inhibitory activities were observed. Once again, compounds were selective
for MAO-A over MAO-B, except for three compounds (82, 84, and 85), which were selective
for MAO-B.
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Compound
81
82
83
84
85
86
87
88
89
90
91
92
Clorgylin
Deprenyl

MAO-A
IC50 (μM)
41.811 ± 9.49
21.193 ± 0.15
2.154 ± 0.13
1.114 ± 0.12
8.165 ± 0.59
2.880 ± 0.08
1.685 ± 0.10
0.204 ± 0.01
0.547 ± 0.04
29.864 ± 1.01
16.023 ± 1.37
12.613 ± 0.27
0.003 ± 0.0004
-

MAO-B
IC50 (μM)
>100
1.02 ± 0.31
8.25 ± 0.07
0.48 ± 0.09
5.64 ± 0.70
41.60 ± 0.27
84.16 ± 2.46
20.34 ± 3.65
29.16 ± 1.44
>100
65.84 ± 3.87
41.30 ± 0.67
0.08 ± 0.02

SIa
2.39
0.04
3.83
0.43
0.69
14.44
49.95
99.71
53.31
3.34
4.11
3.27

a

The relative selectivity for MAO-A is defined by the ratio of
IC50 (MAO-B)/IC50 (MAO-A) for each compound.

Table 3-4 Aplysinopsin analogs 81 - 92 tested for inhibition of human MAO-A and MAO-B
activities.
The most active compounds at MAO-A, 88 and 89, were similar to the previous library of
aplysinopsin analogs, with substitutions at C-5. Reviewing the MAO inhibitory activities of the
N-benzylaplysinopsin derivatives (81 – 85) reveals that overall these compounds were not very
potent. This group did yield the three aforementioned compounds which were more selective for
MAO-B over MAO-A. This is unique, as only one compound of the first series of 50 analogs
(76) was selective for MAO-B over MAO-A. There are no significant structural similarities
between these compounds and compound 76 other than their being unsubstituted on the indole
ring. Compound 84 was the most potent and selective MAO-B inhibitor out of both sets of
analogs. There were other compounds which possessed lower IC50 values for MAO-B than
compound 84, however, they were all even more potent inhibitors of MAO-A. For example,
compound 54 had an IC50 of 0.447 μM for MAO-B, but also had a 0.0056 μM IC50 value for
81

MAO-A.
Compounds 86, 88, and 89 closely resembled the first library of analogs. They were
substituted at C-5 with cyano, fluoro, and methoxy groups, respectively. Compounds 88 and 89
were especially active, with IC50 values in the low micromolar range. These compounds also
displayed significant selectivity for MAO-A over MAO-B, with SI’s of 99 and 54, respectively.
Compounds 87 and 90-92 were all substituted at the indole nitrogen atom. They were all
selective for MAO-A over MAO-B. Compound 87, the N-acetyl derivative, was especially
selective for MAO-A, with an SI of 50. Among the N-alkyl analogs, we observed that the longer
the length of the alkyl chain, the more potent inhibitor of MAO-A the compounds were, with the
N-propyl analog possessing the lowest IC50 of 12.61 μM.
Assessment of MDR-1 efflux pump susceptibility
Efflux pumps are a major obstacle in BBB penetration. Efflux of a drug out of the brain
by the MDR-1 efflux pump could be a cause for the poor in vivo efficacy of lead compounds.
Based on this we sought to evaluate the interaction of aplysinopsin analogs with the MDR-1
efflux pump. This was done in collaboration with the PDSP at UNC-Chapel Hill. They have
developed a live cell assay that allows measurement of the interaction of compounds with the
MDR-1 transporter. It is a fluorescence-based assay that is performed in Caco-2 cells (see
Figure 3-13). Briefly, the assay is based on the ability of MDR-1 to transport calcein
acetoxymethyl ester (calcein-AM) out of cells, but not the free form of calcein. Calcein-AM is
able to passively diffuse into Caco-2 cells, where an esterase can then hydrolyze calcein-AM to
calcein, which is unable to be pumped out. This calcein molecule is highly fluorescent, whereas
calcein-AM is not. Thus, if an assayed compound is subjected to efflux from the cell via MDR-
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1, it will compete with calcein-AM for MDR-1, thus it will lower the amount of calcein-AM
pumped out, and result in a higher rate of conversion of calcein-AM to calcein, and subsequently
increased fluorescence. Hence, the more the compound interacts with MDR-1, the higher the
increase in fluorescence.
Calcein AM =

Compound = X

Calcein =

X

Esterase

Esterase

X

X

X
X

X

X
MDR-1

MDR-1

High Fluorescence

Low Fluorescence
Figure 3-13 MDR-1 susceptibility assay

Ten analogs were initially assayed for their MDR-1 susceptibility, however, problems
establishing statistically relevant signal windows with control compounds have slowed the work,
and some of the results are still pending. Preliminary results for three of the 10 compounds
(compounds 83, 88, and 89) are known of November 24, 2013, there are still some questions
regarding the statistical significance of these results, but they are presented here because they
provide valuable preliminary insights into the possible MDR-1 susceptibility of aplysinopsins.
Re-testing of these three, and testing of the other seven compounds is to be undertaken pending
the reestablishment of the correct assay parameters.
The results of each compound tested are shown below in Figure 3-14. Ideally the
positive control cyclosporin A, a known MDR-1 inhibitor, shows a large increase in
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fluorescence, however, as you can see in Figure 3-14 we only observed a marginal increase in
fluorescence in cells treated with cyclosporin A. This limited signal window from the positive
control makes it difficult to make firm conclusions regarding the percentage increase in
fluorescence due to our compounds. However, it should be noted that based on the small signal
window available none of the three compounds evaluated showed a significant increase in
fluorescence, indicating that they would not be MDR-1 substrates.

Compound 83

Compound 88

Compound 89

Figure 3-14 MDR-1 susceptibility of compounds 83, 88, and 89.
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In vivo evaluation of second generation lead compounds
Based on the in vitro binding data and information from the MDR-1 assay and metabolic
stability assays, three new lead compounds were evaluated in the chick anxiety-depression model
to assess their potential anti-depressant activities. For background and detailed experimental
methodology please see Chapter 2.
Compounds (83, 88, and 89) were evaluated in this round of in vivo testing. Compound
83 was chosen based on it the fact that it was the most potent 5-HT ligand from the second group
of analogs, with a Ki of 493 nM for 5-HT2C. Compounds 88 and 89 were potent and selective
inhibitors of MAO isoform A, with IC50 values of 0.204 μM and 0.547 μM, respectively. In
addition, both were highly selective for MAO-A over MAO-B, with SI values of 99 and 53,
respectively.
In addition to new compounds, other aspects of the assay were altered. During this round
of testing, evaluation periods were extended from 60 to 90 minutes, to observe antidepressant
effects which were missed previously due to delayed onset of effects. Compounds were
evaluated at 1, 3, and 10 mg/kg doses for this round of testing and the positive control was
imipramine at a dose of 1 mg/kg.
Distress vocalizations rates across the isolation test were compiled into five phases that
included the anxiety-like phase (0-3 min) and four quarters of the depression like phase (30-90
min). ANOVAs were performed at each to examine treatment difference of 83, 88 and 89. None
of the test articles showed significant treatment effects in the anxiety-like phase (data not
shown). Further, 88 did not show significant treatment effects during any segment of the
depression-like phase (data not shown). However, 83 and 89 show significant treatment effects
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in the last 2 and 3 quarters of the depression-like phase, respectively; such differences reflect
different onsets of action of these two test articles. For clarity, the data presented below
summarize the treatment effects for the final 2 quarters of the depression-like phase (60-90 min).
The effects of imipramine and 83 on DVocs during the depression-like phase are
summarized in Figure 3-15.

Dep 60-90
90

*

*

80
70

DVoc Rate

60
50
40
30
20
10
0
Vehicle

Imipramine 1
mg/kg

CMPD 83 1 mg/kg CMPD 83 3 mg/kg CMPD 83 10 mg/kg

Treatment

Figure 3-15 The effects of 83 on isolation-induced distress vocalizations (DVocs) for the
final 30 min of the isolation period. Values represent mean ±SEM (n= 17-18). * indicates
significant increase in DVoc compared with vehicle condition.
Chicks tested in the vehicle condition displayed a DVoc rate of 124 in the anxiety phase that
declined to 62 in the depression-like phase illustrating behavioral despair. Imipramine and 10
mg/kg 83 showed anti-depressant activity by attenuating the onset of behavioral despair. A 1way ANOVA on these data failed to reveal a significant treatment effect, F5, 89= 1.877, p=0.122.
However, planned comparisons using Fisher’s LSD analyses revealed that DVocs in the
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imipramine and 10 mg/kg 83 groups were significantly higher than the vehicle group (P < 0.05).
The effects of 1 mg/kg imipramine and three doses of 89 on DVocs during the
depression-like phase are summarized in Figure 3-16. Chicks tested in the vehicle condition
displayed a DVoc rate of 118 in the anxiety phase that declined to 50 in the depression-like
phase illustrating behavioral despair. Imipramine and all doses of 89 showed anti-depressant
activity by attenuating the onset of behavioral despair. Consistent with these observations the 1way ANOVA on these data approached significance, F=2.107, p=0.087. Further, Fisher’s LSD
analyses showed that DVocs in the imipramine, and all 89 groups were significantly higher than
vehicle (P < 0.05).

Dep60-90
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CMPD 89 1 mg/kg
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*

70
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CMPD 89 10 mg/kg

Treatment

Figure 3-16 The effects of 89 on isolation-induced distress vocalizations (DVocs) for the
final 30 min of the isolation period. Values represent mean ±SEM (n = 17-18). * indicates
significant increase in DVoc compared with vehicle condition.
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Conclusions and discussion
We report the design and synthesis of 12 aplysinopsin analogs which were evaluated for
their affinity at 12 serotonin receptors subtypes and 34 other CNS receptors, in addition to
inhibitory activity of MAO isoforms A and B.

Potential compounds were first evaluated using

the QikProp ADME evaluation program. Using this program, several predicted permeability
properties of 400 hundred potential analogs were assessed to improve the in vivo efficacy of
aplysinopsin analogs. In addition to this in silico analysis of potential analogs, the metabolic
stability of compound 53 was evaluated using a rat liver microsomal study. The aplysinopsin
scaffold was not especially labile to phase I metabolism, possessing a T1/2 of 61 minutes and a
Clint of 23 μL/min/mg. These values are well within the range of other antidepressant drugs,
signaling that metabolic stability is not a likely cause of the poor bioavailability of aplysinopsin
analogs. Based on in silico and in vitro studies, a second library of twelve aplysinopsin analogs
was designed, synthesized, and evaluated for their serotonin and MAO activities. N-benzyl
aplysinopsin analogs possessed moderate affinity for serotonin receptor subyptes 5-HT2B and 5HT2C, with the lowest affinity being that of compound 83 for 5-HT2C (Ki = 493 nM). Similar to
the first library of analogs analyzed, the most active compounds did not display significant
selectivity between 5-HT2 receptor subtypes, as compound 83 also had a Ki of 787 nM at 5HT2B. Several N-benzyl compounds also exhibited nanomolar level affinity for the 5-HT3 and
KOR receptors. This is the first report of such affinities by aplysinopsin analogs.
Previous studies have shown the aplysinopsin scaffold to possess affinity for the 5-HT2
receptor subfamily.38, 44 These studies examined the selectivity among serotonin receptor
subtypes 5-HT2A and 5-HT2C. It was shown that halogenation of the indole moiety and the
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pattern of N-alkylations on the imidazolidinone moiety could not only improve Ki values for the
5-HT2 family of receptors, but could also increase selectivity between subtypes 2A and 2C. The
previous evaluations of aplysinopsin analogs’ binding affinities for 5-HT2 subtypes neglected to
evaluate the affinity at 5-HT2B. The 5-HT2B subtype is an important subtype to consider when
designing drug leads, as it has been known to cause serious cardiovascular side effects.102 In
addition, the 5-HT2 receptor subfamily shares a highly conserved sequence of over 80% in
transmembrane domains. Therefore, it is not surprising that many 5-HT2 ligands possess high
affinities for all three 5-HT2 receptor subtypes. The current work examined a large library of
aplysinopsin analogs (31-92), and revealed an overall selectivity for 5-HT2B over 5-HT2A and 5HT2C subtypes.
This initial expanded SAR study of 50 analogs (30-80) confirmed the previous findings
that halogenation of the indole moiety could lead to an increase in the binding affinities at
serotonin receptors. Whereas previous studies only examined brominations at C-5 and C-6, the
current work also considered halogenation of C-4 and C-7, of which C-4 brominated analogs
were among the most potent analogs in each group of compounds. In terms of the N-alkylation
pattern, the results were inconclusive as to the effects on serotonin binding.
During the course of the current work, the first report of the 5-HT2B crystal structure was
published by Wacker et al.78 The structure was elucidated with the LSD precursor ergotamine
(ERG) bound, as shown in Figure 3-17. This work revealed several key structural features of the
5-HT2B binding pocket which may explain the high affinity aplysinopsins have for this particular
serotonin receptor subtype. Of note, the hydrogen bond between threonine (T140) and ERG and
the salt bridge formation between the aspartic acid residue (D135) and ERG appear to be
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important residues for potential aplysinopsin binding.

PDB ID: 4IB4
Wacker et al. Structural features for functional selectivity at
Figure 3-17 Crystal structure of 5-HT2B with ergotamine bound.
serotonin
receptors. Science 2013, 340 (6132), 615-9.
A two dimensional depiction of the binding site is shown below in Figure 3-18.
Replacing ERG with the aplysinopsin scaffold reveals that the two critical binding residues
(T140 and D135) are easily accessible for the aplysinopsin scaffold. This predicted binding
model is in agreement with the previous reports that R2 and R4 should be alkylated to increase
serotonin receptor affinity. When both R2 and R4 are alkylated, the resulting imine at R3 is
easily protonated to allow for the salt bridge formation with D135. This aspartic acid residue is
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conserved in all three 5-HT2 receptor subtypes, possibly explaining the lack of selectivity of
aplysinopsin analogs among this subfamily of receptors. This model of binding would also
explain the lack of activity seen in analogs 81-85 and 87-92, all of which are substituted at the
indole nitrogen. The loss of the ability to form a hydrogen bond with the T140 residue could
explain this loss of serotonin affinity compared to aplysinopsin analogs which are not substituted
at the indole nitrogen.
Future studies will explore more in-depth three dimensional docking studies making use
of the recently elucidated 5-HT2B structure to determine which structural variations of
aplysinopsin analogs are responsible for increasing selectivity among the 5-HT2 receptor family.
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Figure 3-18 Two dimensional representation of ligand interactions in 5-HT2B binding
pocket.
The second library of analogs (81-92) was also evaluated for its MAO inhibitory
activities at isoforms A and B. Analogs substituted at C-5 showed low micromolar level IC50
values. Compounds 88 and 89 were the most potent, with IC50 values of 0.204 μM and 0.547
μM, respectively. These compounds also displayed high selectivity, with SI values of 99 and 53,
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respectively. These results mirrored those seen with the first library of analogs (30-80), which
showed increased MAO-A inhibitory activity and selectivity when C-5 or C-6 were halogenated.
This suggests that substitution at C-5 or C-6 is important for MAO-A potency and selectivity.
Furthermore, this enhanced potency was observed if the substituent was either electron
withdrawing (halogens Br and F) or electron donating (methoxy, compound 89).
The MAO isoforms A and B share a 70% sequence homology.103 However, the active
sites for each enzyme contain 20 enzymes, seven of which are different in MAO-A compared to
MAO-B.104 These changes in active site residues results in MAO-A having a hydrophobic cavity
that is ~ 550 Å3, which is smaller than the MAO-B active site cavity which is ~700 Å3. This
smaller active site cavity could account for the loss of MAO-A inhibitory activity in the second
series of aplysinopsin analogs with bulky benzyl substitutions (81-85) and lengthy alkyl
substitutions at the indole nitrogen (91-92). Another interesting difference between the two
isoforms of MAO is that MAO-A crystalizes as a monomer, whereas MAO-B presents as a
dimer, as shown in Figure 3-19. The binding of deprenyl and clorgyline reveal that the critical
changes in active site residues are the change of Phe-208 in MAO-A to Ile-199 in MAO-B; and
Ile-335 to Tyr-326 in MAO-B. As mentioned previously, the width and depth of the binding
cavities varies widely from MAO-A to MAO-B. In an effort to explain why aplysinopsins are
selective for MAO-A, we are currently designing docking and molecular dynamics studies to
give insight into the selectivity between MAO-A and MAO-B.
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Based on these in vitro screening findings, three lead compounds were further evaluated
in an in vivo model. Compounds 83, 88, and 89 were evaluated in the chick-anxiety depression
model. Compound 83, the p-chloro-N-benzylaplysinopsin analog, showed a modest
antidepressant effect at a dose of 10 mg/kg in the later phases of the assay. This delay in onset
was seen previously with compound 33, which also has a high affinity for serotonin receptor
subtypes. Compound 89, the 5-methoxyaplysinopsin analog, displayed potent antidepressant
activity, attenuating behavioral despair at all doses. In contrast, the 5-fluoroaplysinopsin analog
(88) showed no antidepressant activity across all doses.
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Experimental
Chemistry
Unless specified all reagents were purchased from commercial sources and used without
further purification. Compounds were purified via column chromatography using Sorbtech
silica gel, 60A, 40-63um from Sorbent Technologies. Whatman silica gel F254 polyester backed
plates were used for TLC and visualized with UV light and/or ninhydrin, vanillin, and
anisaldehyde. NMR spectra were recorded on a 400 MHz Bruker instrument (400 UltraShield,
54 mm standard magnet bore, Billerica, MA) with 3mm direct carbon probe. 1H-NMR and 13CNMR spectra were recorded at 400 MHz and 100 MHz, respectively. Chemical shifts were
standardized to TMS and solvent signals. All biologically evaluated compounds were found to
possess ≥ 95% purity by HPLC (UV detection at 210 and 254 nm). Purified samples were
analyzed by LC-MS (Bruker Daltonic microTOF, Leipzig Germany) using a 150 x 4.6 mm C8
column (Luna Phenomenex). HR-ESI-MS analysis was done in positive ionization mode.
General procedures for the synthesis of each group of aplysinopsin analogs and full
characterizations of three compounds evaluated in vivo are provided below. Analytical data for
all other compounds can be found in Chapter 5.
General procedure for the synthesis of N-benzyl aplysinopsin analogs (81-85)
To a solution of 3-formylindole (2.4 mmol, 348 mg) in EtOH (20 mL) at room
temperature, KOH pellets (3 mmol, 170 mg) were added and the mixture was stirred until
maximum solubilization was achieved. The EtOH was removed under vacuum and 20 mL of
acetone was added. This was followed by the addition of the appropriate benzyl bromide (2.4
mmol). A precipitate was formed instantly, and was filtered off and the solution concentrated to
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yield the N-benzyl substituted 3-formylindoles. They were used in the next step without further
purification.
Next, the appropriate N-benzyl-3-formylindoles (0.24 mmol) were dissolved in ethylene
glycol (0.25 mL). A solution of imidazolidinone 28 (0.36 mmol, 91.8 mg) in ethylene glycol
(0.25 mL) was added and the mixture was heated at 130°C for 2h. Additional 28 was added
(0.12 mmol, 30.6 mg) in ethylene glycol (0.25 mL) and the reaction mixture heated for another
2h at 130°C. The mixture was cooled, diluted with H2O (30 mL) and extracted with EtOAC (4 x
30 mL). The organic layers were combined, washed with H2O (4 x 25 mL), and dried with
MgSO4. After filtering and concentration, the crude product was purified using flash
chromatography (dichlormethane-methanol, 9:1) to yield the N-benzylaplysinopsin analogs 8185.
General procedure for the synthesis of analogs substituted on the indole moiety (86, 88, 89)
Equimolar amounts of the appropriate 3-formylindoles (5-cyano, 5-fluoro, 5-methoxy)
and imidazolidinone 28 were mixed under nitrogen and heated over an open flame until the
reaction mixture began effervescing. Several minutes after the mixture stopped effervescing it
was cooled to room temperature. The crude mixture was extracted with MeOH and insoluble
materials filtered off. The solution was concentrated and loaded on silica gel for purification
using.
General procedure for the synthesis of analogs substituted at the indole nitrogen (87, 90-92)
For compounds 90-92, 3-formylindole (2.5 mmol, 363 mg) and KOH (5 mmol, 280 mg)
were dissolved in 10 mL DMSO. Appropriate alkyl iodide (5 mmol) was added, and the solution
was stirred at room temperature and monitored via TLC until the total consumption of the
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starting material. The solution was diluted with H2O (10 mL) and extracted with EtOAc (3 x 15
mL). They solution was then concentrated and the N-substituted 3-formylindoles were
crystallized and used in the following condensation step without further purification. These
intermediates were then subjected to the condensation conditions.
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Figure 3-20 1H and 13C NMR spectra of compound 83.
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Figure 3-21 1H and 13C NMR spectra of compound 88.
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Figure 3-22 1H and 13C NMR spectra of compound 89.
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(E)-5-[(1-(2-chlorobenzyl)-1H-indol-3-yl)methylene]- 2-imino-1,3-dimethylimidazolidin-4one (83)
1

H NMR (400 MHz, DMSO) δ 9.36 (s, 1H), 9.02 (s, 1H), 8.14 (d, J = 6.5 Hz, 1H), 7.61

(d, J = 7.8 Hz, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.38 (t, J = 7.4 Hz, 1H), 7.30 (dd, J = 12.7, 5.0 Hz,
4H), 7.05 (d, J = 7.5 Hz, 1H), 5.67 (s, 2H), 3.52 (s, 3H), 3.19 (s, 3H).

13

C NMR (101 MHz,

DMSO) δ 160.64, 152.57, 136.46, 134.57, 134.40, 132.98, 130.33, 130.24, 129.97, 128.73,
128.16, 123.64, 122.97, 121.71, 119.39, 115.18, 111.50, 108.81, 48.22, 29.33, 26.67. HRESMS
m/z calcd 379.1326 (M.+ +H); found: 379.1335.
(E)-5-[(5-fluoro-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (88)
1

H NMR (400 MHz, DMSO) δ 11.62 (s, 1H), 8.71 (s, 1H), 8.16 (s, 1H), 7.38 (d, J = 8.6

Hz, 1H), 7.24 (dd, J = 8.5, 1.4 Hz, 1H), 6.42 (s, 1H), 3.25 (s, 3H), 3.05 (s, 3H).

13

C NMR (101

MHz, DMSO) δ 160.16, 152.02, 134.56, 132.21, 129.61, 125.29, 122.41, 121.22, 115.25, 114.36,
113.75, 108.24, 28.97, 26.28. HRESMS m/z calcd 273.1152 (M.+ +H); found: 273.1148
(E)-5-[(5-methoxy-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (89)
1

H NMR (400 MHz, DMSO) δ 11.92 (s, 1H), 9.27 (s, 1H), 8.95 (d, J = 3.0 Hz, 1H), 7.60

(d, J = 2.0 Hz, 1H), 7.40 (d, J = 8.7 Hz, 1H), 7.30 (s, 1H), 6.87 (dd, J = 8.7, 2.3 Hz, 1H), 3.85 (s,
3H), 3.52 (s, 3H), 3.20 (s, 3H).

13

C NMR (101 MHz, DMSO) δ 160.05, 154.97, 151.65, 131.75,

130.71, 128.57, 121.18, 116.29, 113.06, 112.55, 108.51, 100.86, 55.71, 28.98, 26.16. HRESMS
m/z calcd 285.1352 (M.+ +H); found: 285.1350.
Bioassay
In vitro stability study and metabolism profiling
Compound 53 was solubilized in DMSO at 10 mM, and incubated in duplicate with rat
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liver microsomes at 37°C in 1000 μL volume. The reaction mixture contains 0.5 mg liver
microsomal protein in 0.5 M potassium phosphate pH, NADPH Regenerating System Solution A
and B (BD Biosciences) and 1 μL substrate in DMSO (5 μM final concentration). A control is
run for each test compound without NADPH to detect NADPH-free degradation. At 15, 30, and
60 min, 100 μL is removed from each experimental and mixed with 100 μL acetonitrile
containing internal standards. After centrifugation the supernatants are analyzed by LC-MS to
quantitate the remaining parent. The sample analysis is performed by LC-MS with an Agilent
1100 HPLC equipped with a diode array detector and Micromass Quatro Micro API. Data were
analyzed using masslynx and quanlynx. The LC conditions are as follows: flow rate: 0.5
mL/min; Accucore C18 2.1x50 mm column, gradient from 95% water (0.1% formic acid) to
95% acetonitrile (0.1% formic acid) over 8 minutes.
Data are converted to % remaining by dividing the time zero concentration value. Data
are fit to a first-order decay model to determine half-life. Intrinsic clearance is calculated from
the half-life and the protein concentration. Incubation samples were analyzed to detect
metabolites. LC-MS data was processed using metabolynx software to generate structural
hypothesis based on daughter ion data.
MDR-1 efflux pump
Modulation of MDR-1 activity is monitored in Caco-2 cells derived from the human
colonic epithelium or HEK human kidney cells. The assay monitors the time-depenedent
increase in calcein fluorescence in live cells in 96 well plates. Cells are seeded into 96-well
culture plates 24h prior to assay at 80,000 cells per well. The medium is removed and 50 μL of
D-PBS, 10 mM glucose (negative control), test compound (25 μM), or reference compound
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(cyclosporin A) (25 μM). The cells are incubated at 37°C for 30 min. Next calcein-AM is added
to the cells at a final concentration of 500 nM). Fluorescence is monitored over a 4 minute
period by a FlexStation II fluorimeter (Molecular Devices). Compounds are assayed in
quadruplicate and each assay will contain wells with no test compound (negative control) and
wells with 25 μM cyclosporin A (positive control). Results for test compounds are calculated
from the slope of fluorescence increase and are normalized so that the value for untreated cells is
0% and the value for cyclosporin A is 100%.
In vitro evaluation of CNS receptor binding affinity
Ki determinations were generously provided by the National Institute of Mental Health's
Psychoactive Drug Screening Program. Briefly, compounds are initially evaluated in a primary
binding assay, in which they are tested at a final concentration of 10 μM. They are tested in
quadruplicate and compounds that show > 50% inhibition are deemed hits and advance to
secondary radioligand binding assays. Here compounds are tested at 11 concentrations (0.1, 0.3,
1, 3, 10, 30, 100, 300 nM, 1, 3, 10 μM) to determine the Ki values at specific receptors. For
complete experimental details please refer to the PDSP web site http://pdsp.med.unc.edu/ and
click on "Binding Assay" on the menu bar.
In vitro evaluation of MAO inhibitory activity
An in vitro assay was designed to measure the effect of aplysinopsin analogs on MAO-A
and B activity. Recombinant human MAO-A and B were obtained from BD Biosciences
(Bedford, MA, USA). Kynuramine bromide, 4-hydroxyquinoline, clorgyline and R-(-)-deprenyl
were purchased from Sigma (St Louis, MO, USA). Aplysinopsin analogs (10-9 to 10-2M),
clorgyline and deprenyl (10-12 to 10-5M) were tested for inhibition of human MAO-A and B
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activity. MAO-activity was assessed by a modification of the fluorometric method of Kralj79 and
was adopted for 96 well plate format. The 200 µL reaction mixtures containing recombinant
human MAO-A or MAO-B (5 µg/ml) and the test compounds in KH2PO4 buffer (100 mM; pH
7.4) were pre-incubated at 37oC for 15 min. The reactions with positive control wells with
standard MAO inhibitors and controls without inhibitors were also set up simultaneously. The
reaction was initiated by addition of kynuramine (250 µM) in potassium phosphate buffer (100
mM; pH 7.4) and incubated further at 37oC for 20 min. After incubation the reaction was stopped
by the addition of 75 µL of 2N NaOH. The deaminated product of kynuramine, which
spontaneously cyclizes to 4-hydroxyquinoline, was determined fluorometrically at 320 nm
excitation and 460 nm emission wavelengths in a plate reader (SpectraMax M5, Molecular
Devices, Sunnyvale, CA, USA). Wells receiving no test compounds were used as controls to
calculate the inhibition percentage. The IC-50 values were computed from the dose response
inhibition curves prepared by GraphPad.
In vivo evaluation of aplysinopsin analogs
All procedures involving animals were performed as approved by the Institutional
Animal Care and Use Committee of The University of Mississippi. Cockerels (Production Red,
Ideal Poultry, Cameron, TX, USA) were received into the laboratory at 2 days post hatch and
housed in 34 x 57 x 40 cm cages with 12 chicks per cage. Food and water are available ad
libitum via gravity feeders. Daily maintenance that entails the replacement of tray liners and
filling food and water gravity feeders is conducted during the hour that precedes the animal’s
dark cycle. Lights are operated on a 12:12 light dark cycle. Supplemental heating sources are
provided to maintain appropriate housing temperatures in the range of 32 +/- 1oC.
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Testing equipment
A six unit testing apparatus containing Plexiglas chambers (25 x 25 x 22 cm) surrounded
by sound attenuating media is used to record separation-induced vocalizations. Each unit is lined
with acoustical fiber media, illuminated by a 25-W light bulb, and ventilated by an 8-cmdiameter rotary fan (Model FP-108AX S1, Commonwealth Industrial Corp., Taipei, Taiwan).
Miniature video cameras (Model PC60XP, SuperCircuits, Inc., Liberty Hill, TX) mounted in the
sound-attenuating enclosures at floor level and routed through a multiplexor (Model PC47MC,
SuperCircuits, Inc.) provided televised display of the chicks for behavioral observation. To
record DVocs, microphones (Radio Shack Omnidirectional Model 33-3013 modified for AC
current) are mounted at the top of the Plexiglas chamber. These vocalizations are routed to a
computer equipped with custom designed software for data collection.
Methods
Squads of six chicks were taken from their home cage and placed within a lidded plastic
transport container. To track subject assignment to treatment conditions, chicks are marked
using colored felt pens and body weight is determined for each chick to determine dosing and
identify outliers (i.e., low body weight). Drugs were administered IP 15 minutes prior to
behavioral testing. Chicks were placed into individual testing units for a 60 minute session.
Following the completion of the session chicks were removed from the testing apparatus and
returned to their home cage.
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4. NMR data for compounds 31-80
(Z)-5-[(1H-indol-3-yl)methylene]-2-amino-1H-imidazol-4(5H)-one (31): 1H NMR (400
MHz, DMSO) δ 11.69 (s, 1H), 8.07 (s, 1H), 7.81 (d, J = 7.7 Hz, 1H), 7.43 (d, J = 7.9 Hz, 1H),
7.18 – 7.13 (m, 1H), 7.10 (t, J = 7.4 Hz, 1H), 6.75 (s, 1H).

13

C NMR (101 MHz, DMSO) δ

172.65, 160.79, 136.36, 127.82, 127.24, 122.53, 120.38, 118.85, 118.20, 112.32, 110.61, 104.96.
HRESMS m/z calcd 227.0933 (M.+ +H); found: 227.0940.
(Z)-2-amino-5-[(4-bromo-1H-indol-3-yl)methylene]-1H-imidazol-4(5H)-one (32): 1H
NMR (400 MHz, DMSO) δ 11.87 (s, 1H), 8.52 (s, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.27 (d, J = 8.0
Hz, 1H), 7.04 (t, J = 8.0 Hz, 1H), 6.87 (s, 1H).

13

C NMR (DMSO) δ (ppm): 172.35, 157.48,

137.24, 132.38, 130.98, 127.28, 125.76, 122.29, 115.87, 112.25, 110.13, 104.48. HRESMS m/z
calcd 305.0038 (M.+ +H); found: 305.0069.
(Z)-2-amino-5-[(5-bromo-1H-indol-3-yl)methylene]-1H-imidazol-4(5H)-one (33): 1H
NMR (400 MHz, DMSO) δ 11.72 (s, 1H), 8.06 (s, 1H), 7.38 (d, J = 8.5 Hz, 1H), 7.24 (d, J = 8.5
Hz, 1H), 6.59 (s, 1H).

13

C NMR (101 MHz, DMSO) δ 168.36, 164.54, 137.31, 135.03, 128.95,

125.35, 124.79, 121.68, 119.28, 114.19, 112.78, 102.97. HRESMS m/z calcd 305.0038 (M.+
+H); found: 305.0040.
(Z)-2-amino-5-[(6-bromo-1H-indol-3-yl)methylene]-1H-imidazol-4(5H)-one (34): 1H
NMR (400 MHz, DMSO) δ 11.66 (s, 1H), 8.05 (s, 1H), 7.82 (d, J = 7.9 Hz, 1H), 7.61 (s, 1H),
7.19 (d, J = 8.1 Hz, 1H), 6.60 (s, 1H). 13C NMR (101 MHz, DMSO) δ 173.60, 163.59, 137.06,
131.59, 129.78, 126.20, 123.89, 123.10, 114.49, 112.89, 110.63, 105.21. HRESMS m/z calcd
305.0038 (M.+ +H); found: 305.0035.
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(Z)-2-amino-5-[(7-bromo-1H-indol-3-yl)methylene]-1H-imidazol-4(5H)-one (35): 1H
NMR (400 MHz, DMSO) δ 11.65 (s, 1H), 8.24 (s, 1H), 7.87 (s, 1H), 7.36 (d, J = 6.1 Hz, 1H),
7.08 – 6.97 (m, 1H), 6.60 (s, 1H).

13

C NMR (101 MHz, DMSO) δ 171.84, 158.03, 134.65,

132.20, 128.92, 124.90, 124.84, 121.48, 118.63, 113.42, 109.65, 104.89. HRESMS m/z calcd
305.0038 (M.+ +H); found: 305.0043.
(E)-5-[(1H-indol-3-yl)methylene]-2-amino-1-methyl-1H-imidazol-4(5H)-one (36): 1H
NMR (400 MHz, DMSO) δ 11.47 (s, 1H), 9.10 (d, J = 2.4 Hz, 1H), 7.89 (d, J = 7.6 Hz, 1H),
7.43 (d, J = 7.7 Hz, 1H), 7.20 – 7.04 (m, 2H), 6.55 (s, 1H), 3.29 (s, 3H). 13C NMR (DMSO) δ
(ppm): 175.96, 165.44, 136.02, 131.24, 129.07, 128.19, 122.07, 119.88, 118.42, 112.22, 109.45,
105.11, 28.27. HRESMS m/z calcd 241.1089 (M.+ +H); found: 241.1091.
(E)-2-amino-5-[(4-bromo-1H-indol-3-yl)methylene]-1-methyl-1H-imidazol-4(5H)-one
(37): 1H NMR (DMSO, 400 MHz) δ 11.82 (s, 1H), 9.21 (s, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.42 (s,
1H), 7.29 (d, J = 8.0 Hz, 1H), 7.04 (t, J = 8.0 Hz, 1H), 3.23 (s, 3H); 13C NMR (101 MHz,
DMSO) δ 175.73, 165.40, 137.80, 131.10, 130.93, 125.10, 124.35, 123.11, 113.21, 112.45,
109.65, 105.89, 28.30. HRESMS m/z calcd 319.0194 (M.+ +H); found: 319.0151.
(E)-2-amino-5-[(5-bromo-1H-indol-3-yl)methylene]-1-methyl-1H-imidazol-4(5H)-one
(38): 1H NMR (400 MHz, DMSO) δ 11.60 (s, 1H), 9.11 (d, J = 2.0 Hz, 1H), 8.17 (s, 1H), 7.39 (d,
J = 8.5 Hz, 1H), 7.24 (dd, J = 8.5, 1.6 Hz, 1H), 6.53 (s, 1H), 3.28 (s, 3H). 13C NMR (101 MHz,
DMSO) δ 175.90, 165.58, 134.72, 133.13, 131.75, 130.07, 124.52, 121.13, 114.17, 112.80,
109.38, 104.56, 28.35. HRESMS m/z calcd 319.0194 (M.+ +H); found: 319.0198.
(E)-2-amino-5-[(6-bromo-1H-indol-3-yl)methylene]-1-methyl-1H-imidazol-4(5H)-one
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(39): 1H NMR (400 MHz, DMSO) δ 11.53 (s, 1H), 9.06 (s, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.60
(d, J = 1.3 Hz, 1H), 7.22 (dd, J = 8.5, 1.4 Hz, 1H), 6.48 (s, 1H), 3.26 (s, 3H). 13C NMR (101
MHz, DMSO) δ 175.80, 165.48, 136.73, 131.38, 130.74, 125.29, 124.57, 124.10, 113.42, 112.30,
109.23, 105. 73, 28.29. HRESMS m/z calcd 319.0194 (M.+ +H); found: 319.0194.
(E)-2-amino-5-[(7-bromo-1H-indol-3-yl)methylene]-1-methyl-1H-imidazol-4(5H)-one
(40): 1H NMR (DMSO, 400 MHz) δ (ppm): 11.64 (s, 1H), 9.14 (s, 1H), 7.93 (d, J = 8.0 Hz, 1H),
7.36 (d, J = 8.0 Hz, 1H), 7.05 (t, J = 8.0, 1H), 6.48 (s, 1H), 3.27 (s, 3H) ; 13C NMR (101 MHz,
DMSO) δ 175.93, 165.74, 134.35, 132.15, 129.89, 124.63, 121.25, 118.19, 110.70, 104.89(d),
104.22, 28.28. HRESMS m/z calcd 319.0194 (M.+ +H); found: 319.0198.
(Z)-4-[(1H-indol-3-yl)methylene]-2-amino-1-methyl-1H-imidazol-5(4H)-one (41): 1H
NMR (400 MHz, DMSO) δ 11.50 (s, 1H), 8.21 (s, 1H), 7.91 (d, J = 7.7 Hz, 1H), 7.41 (d, J = 7.8
Hz, 1H), 7.21 – 6.99 (m, 2H), 6.76 (s, 1H), 3.05 (s, 3H). 13C NMR (101 MHz, DMSO) δ 169.60,
157.84, 136.29, 129.26, 127.16, 122.32, 120.20, 119.13, 112.88, 112.21, 111.89, 107.53, 26.00.
HRESMS m/z calcd 241.1089 (M.+ +H); found: 241.1084.
(Z)-2-amino-4-[(4-bromo-1H-indol-3-yl)methylene]-1-methyl-1H-imidazol-5(4H)-one
(42): 1H NMR (400 MHz, DMSO) δ 11.88 (s, 1H), 8.57 (s, 1H), 7.57 (s, 1H), 7.46 (d, J = 8.0 Hz,
1H), 7.27 (d, J = 7.5 Hz, 1H), 7.04 (t, J = 7.8 Hz, 1H), 3.04 (s, 3H). 13C NMR (101 MHz,
DMSO) δ 173.45, 158.36, 137.73, 136.39, 131.47, 124.84, 124.23, 123.23, 113.54, 112.40,
112.28, 107.30, 26.00. HRESMS m/z calcd 319.0194 (M.+ +H); found: 319.0196.
(Z)-2-amino-4-[(5-bromo-1H-indol-3-yl)methylene]-1-methyl-1H-imidazol-5(4H)-one
(43): 1H NMR (400 MHz, DMSO) δ 11.67 (s, 1H), 8.22 (s, 1H), 8.18 (s, 1H), 7.37 (d, J = 8.5 Hz,
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1H), 7.24 (dd, J = 8.6, 1.4 Hz, 1H), 6.73 (s, 1H), 3.04 (s, 3H). 13C NMR (101 MHz, DMSO) δ
163.45, 154.34, 134.68, 132.60, 129.02, 123.29, 121.98, 121.39, 114.58, 114.05, 113.89, 105.78,
26.69. HRESMS m/z calcd 319.0194 (M.+ +H); found: 319.0154.
(Z)-2-amino-4-[(6-bromo-1H-indol-3-yl)methylene]-1-methyl-1H-imidazol-5(4H)-one
(44): 1H NMR (400 MHz, DMSO) δ 11.58 (s, 1H), 8.19 (s, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.60 (s,
1H), 7.17 (dd, J = 8.5, 1.3 Hz, 1H), 6.70 (s, 1H), 3.04 (s, 3H).

13

C NMR (101 MHz, DMSO)

δ163.34, 153.71, 137.39, 133.03, 127.02, 123.97, 123.31, 121.10, 115.78, 113.29, 112.75,
105.57, 26.10. HRESMS m/z calcd 319.0194 (M.+ +H); found: 319.0144.
(Z)-2-amino-4-[(7-bromo-1H-indol-3-yl)methylene]-1-methyl-1H-imidazol-5(4H)-one
(45): 1H NMR (400 MHz, DMSO) δ 11.66 (s, 1H), 8.28 (s, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.35
(d, J = 7.5 Hz, 1H), 7.02 (t, J = 7.7 Hz, 1H), 6.71 (s, 1H), 3.04 (s, 3H).

13

C NMR (101 MHz,

DMSO) δ 165.85, 153.49.29, 134.60, 131.07, 129.10, 124.69, 122.38, 114.25, 112.69, 105.87,
105.34, 103.21, 25.88. HRESMS m/z calcd 319.0194 (M.+ +H); found: 319.0138.
(E)-5-[(1H-indol-3-yl)methylene]-1-methyl-2-(methylamino)-1H-imidazol-4(5H)-one
(46): 1H NMR (400 MHz, DMSO) δ 11.48 (s, 1H), 9.09 (s, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.43 (d,
J = 7.8 Hz, 1H), 7.12 (dt, J = 14.7, 6.9 Hz, 2H), 6.55 (s, 1H), 3.26 (s, 3H), 2.91 (s, 3H).

13

C

NMR (101 MHz, DMSO) δ 162.03, 153.21, 135.87, 130.91, 127.50, 122.48, 122.20, 120.75,
118.65, 115.08, 112.36, 108.56, 29.01, 26.24. HRESMS m/z calcd 255.1246 (M.+ +H); found:
255.1301.
(E)-5-[(4-bromo-1H-indol-3-yl)methylene]-1-methyl-2-(methylamino)-1H-imidazol4(5H)-one (47): 1H NMR (400 MHz, DMSO) δ 11.82 (s, 1H), 9.21 (s, 1H), 7.47 (d, J = 7.7 Hz,
1H), 7.43 (s, 1H), 7.29 (d, J = 7.5 Hz, 1H), 7.04 (t, J = 7.8 Hz, 1H), 3.20 (s, 3H), 2.90 (s, 3H).
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13

C NMR (101 MHz, DMSO) δ 171.84, 159.82, 137.69, 133.18, 128.44, 125.89, 124.34, 115.44,

113.67, 112.19, 109.69, 102.01, 31.56, 28.16. HRESMS m/z calcd 333.0351 (M.+ +H); found:
333.0321.
(E)-5-[(5-bromo-1H-indol-3-yl)methylene]-1-methyl-2-(methylamino)-1H-imidazol4(5H)-one (48): 1H NMR (400 MHz, DMSO) δ 11.60 (s, 1H), 9.09 (s, 1H), 8.33 (s, 1H), 7.49 (d,
J = 8.6 Hz, 1H), 7.24 (d, J = 8.5 Hz, 1H), 6.54 (s, 1H), 3.26 (s, 3H), 2.91 (s, 3H).

13

C NMR (101

MHz, DMSO) δ 169.35, 153.20, 136.00, 135.39, 133.71, 129.06, 122.88, 122.10, 114.05, 113.29,
108.38, 104.24, 30.11, 28.35. HRESMS m/z calcd 333.0351 (M.+ +H); found: 333.0358.
(E)-5-[(6-bromo-1H-indol-3-yl)methylene]-1-methyl-2-(methylamino)-1H-imidazol4(5H)-one (49): 1H NMR (400 MHz, DMSO) δ 11.53 (s, 1H), 9.05 (s, 1H), 8.67 (s, 1H), 7.86
(dd, J = 8.4, 4.8 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 6.50 (s, 1H), 3.24 (s, 3H), 2.91 (s, 3H).

13

C

NMR (101 MHz, DMSO) δ 168.97, 151.08, 136.89, 136.39, 132.20, 129.63, 122.75, 120.59,
114.79, 114.75, 109.43, 101.64, 28.11, 27.53. HRESMS m/z calcd 333.0351 (M.+ +H); found:
333.0298.
(E)-5-[(7-bromo-1H-indol-3-yl)methylene]-1-methyl-2-(methylamino)-1H-imidazol4(5H)-one (50): 1H NMR (400 MHz, DMSO) δ 11.62 (s, 1H), 9.11 (s, 1H), 7.93 (d, J = 7.9 Hz,
1H), 7.36 (d, J = 7.2 Hz, 1H), 7.05 (t, J = 7.7 Hz, 1H), 6.49 (s, 1H), 3.25 (s, 3H), 2.92 (s, 3H).
13

C NMR (101 MHz, DMSO) δ 169.22, 153.59, 137.97, 135.02, 128.74, 130.19, 127.25, 125.38,

120.19, 115.23, 108.34, 104.34, 31.07, 28.20. HRESMS m/z calcd 333.0351 (M.+ +H); found:
333.0348.
(E)-5-[(1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (51): 1H NMR
(400 MHz, DMSO) δ 11.46 (s, 1H), 8.70 (s, 1H), 7.86 (d, J = 7.7 Hz, 1H), 7.42 (d, J = 7.8 Hz,
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1H), 7.12 (dt, J = 14.5, 7.0 Hz, 2H), 6.42 (s, 1H), 3.25 (s, 3H), 3.06 (s, 3H).

13

C NMR (101

MHz, DMSO) δ 160.53, 152.24, 136.22, 131.67, 128.14, 123.24, 122.25, 121.20, 118.95, 116.21,
112.80, 108.94, 29.30, 26.65. HRESMS m/z calcd 255.1246 (M.+ +H); found: 255.1290.
(E)-5-[(4-bromo-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (52):
1

H NMR (400 MHz, DMSO) δ 11.79 (s, 1H), 8.68 (s, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.28 (d, J =

7.6 Hz, 1H), 7.25 (s, 1H), 7.03 (t, J = 7.8 Hz, 1H), 3.20 (s, 3H), 3.04 (s, 3H).

13

C NMR (101

MHz, DMSO) δ 169.03, 157.38, 137.08, 136.34, 129.04, 128.81, 127.44, 123.95, 120.21, 114.63,
110.05, 105.24, 30.82, 26.30. HRESMS m/z calcd 333.0351 (M.+ +H); found: 333.0348.
(E)-5-[(5-bromo-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (53):
1

H NMR (400 MHz, DMSO) δ 12.17 (s, 1H), 8.96 (s, 1H), 8.37 (s, 1H), 7.47 (d, J = 8.5 Hz, 1H),

7.34 (d, J = 8.5 Hz, 1H), 7.28 (s, 1H), 3.48 (s, 3H), 3.19 (s, 3H).

13

C NMR (101 MHz, DMSO) δ

160.56, 152.42, 134.96, 132.62, 130.02, 125.69, 122.81, 121.62, 115.65, 114.76, 114.15, 108.64,
29.37, 26.69. HRESMS m/z calcd 333.0351 (M.+ +H); found: 333.0351.
(E)-5-[(6-bromo-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (54):
1

H NMR (400 MHz, DMSO) δ 12.07 (s, 1H), 8.93 (s, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.69 (s, 1H),

7.34 (d, J = 8.4 Hz, 1H), 7.23 (s, 1H), 3.48 (s, 3H), 3.19 (s, 3H).

13

C NMR (101 MHz, DMSO) δ

160.53, 152.49, 137.09, 132.25, 127.21, 123.90, 122.92, 120.94, 115.84, 115.47, 115.35, 109.00,
29.37, 26.70. HRESMS m/z calcd 333.0351 (M.+ +H); found: 333.0352.
(E)-5-[(7-bromo-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (55):
1

H NMR (DMSO, 400 MHz) δ 11.63 (s, 1H), 8.73 (s, 1H), 7.90 (d, J = 8 Hz, 1H), 7.36 (d, J =

7.6 Hz, 1H), 7.04 (t, J = 7.6 Hz, 1H), 6.37 (s, 1H), 3.24 (s, 3H), 3.05 (s, 3H). 13C NMR (101
MHz, DMSO) δ 169.27, 163.99, 137.34, 134.68, 129.65, 129.40, 127.84, 125.12, 121.83, 118.53,
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109.32, 104.91, 31.17, 25.80. HRESMS m/z calcd 333.0351 (M.+ +H); found: 333.0352.
(Z)-4-[(1H-indol-3-yl)methylene]-1-methyl-2-(methylamino)-1H-imidazol-5(4H)-one
(56): 1H NMR (400 MHz, DMSO) δ 11.46 (s, 1H), 8.40 (s, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.44
(d, J = 7.8 Hz, 1H), 7.10 (m, 2H), 6.67 (s, 1H), 3.06 (s, 3H), 2.98 (s, 3H).

13

C NMR (101 MHz,

DMSO) δ 166.33, 154.84, 135.22, 135.68, 131.67, 128.14, 127.24, 121.70, 119.90, 114.50,
111.80, 109.94, 27.24, 25.30. HRESMS m/z calcd 255.1246 (M.+ +H); found: 255.1187.
(Z)-4-[(4-bromo-1H-indol-3-yl)methylene]-1-methyl-2-(methylamino)-1H-imidazol5(4H)-one (57): 1H NMR (400 MHz, MeOD) δ 8.58 (s, 1H), 7.97 (s, 1H), 7.42 (d, J = 8.1 Hz,
1H), 7.30 (d, J = 7.5 Hz, 1H), 7.04 (t, J = 7.9 Hz, 1H), 3.14 (s, 3H), 3.09 (s, 3H).

13

C NMR (101

MHz, DMSO) δ 170.05, 156.76, 138.04, 136.87, 131.66, 125.18, 124.09, 120.29, 112.97, 112.30,
110.92, 104.34, 27.19, 25.01. HRESMS m/z calcd 333.0351 (M.+ +H); found: 333.0367.
(Z)-4-[(5-bromo-1H-indol-3-yl)methylene]-1-methyl-2-(methylamino)-1H-imidazol5(4H)-one (58): 1H NMR (400 MHz, MeOD) δ 8.26 (s, 1H), 8.17 (s, 1H), 7.33 (d, J = 8.5 Hz,
1H), 7.27 (d, J = 8.6 Hz, 1H), 6.96 (s, 1H), 3.14 (s, 3H), 3.11 (s, 3H).

13

C NMR (101 MHz,

DMSO) δ 171.31, 167.27, 135.12, 134.21, 127.55, 126.25, 123.29, 120.88, 115.20, 114.23,
110.62, 105.01, 28.03, 26.12. HRESMS m/z calcd 333.0351 (M.+ +H); found: 333.0321.
(Z)-4-[(6-bromo-1H-indol-3-yl)methylene]-1-methyl-2-(methylamino)-1H-imidazol5(4H)-one (59): 1H NMR (DMSO, 400 MHz) δ (ppm): 1H NMR (400 MHz, MeOD) δ 8.22 (s,
1H), 7.82 (d, J = 8.5 Hz, 1H), 7.58 (s, 1H), 7.24 (d, J = 7.3 Hz, 1H), 7.00 (s, 1H), 3.14 (s, 3H),
3.10 (s, 3H).

13

C NMR (101 MHz, DMSO) δ 163.03, 153.56, 136.79, 134.55, 128.21, 123.45,

123.29, 121.03, 113.98, 113.47, 112.25, 108.89, 27.37, 25.40. HRESMS m/z calcd 333.0351
(M.+ +H); found: 333.0329.
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(Z)-4-[(7-bromo-1H-indol-3-yl)methylene]-1-methyl-2-(methylamino)-1H-imidazol5(4H)-one (60): 1H NMR (400 MHz, MeOD) δ 8.33 (s, 1H), 7.88 (d, J = 7.7 Hz, 1H), 7.36 (d, J
= 7.6 Hz, 1H), 7.06 (t, J = 7.8 Hz, 1H), 7.01 (s, 1H), 3.15 (s, 3H), 3.11 (s, 3H).

13

C NMR (101

MHz, DMSO) δ 167.72, 155.58, 135.20, 130.18, 127.98, 125.41, 125.05, 123.56, 118.23, 110.39,
108.34, 104.38, 26.89, 25.07. HRESMS m/z calcd 333.0351 (M.+ +H); found: 333.0339.
(5E)-5-[(1H-indol-3-yl)methylene]-1,3-dimethyl-2-(methylimino)imidazolidin-4-one (61):
1

H NMR (400 MHz, DMSO) δ 8.75 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 8.0 Hz, 1H),

7.22 (m, 2H), 6.99 (s, 1H), 3.30 (s, 3H), 3.15 (s, 3H), 3.10 (s, 3H).

13

C NMR (DMSO) δ (ppm):

175.22, 163.68, 136.34, 132.45, 128.11, 125.67, 123.18, 121.06, 119.24, 112.14, 110.01, 108.87,
32.87, 31.23, 26.80. HRESMS m/z calcd 269.1402 (M.+ +H); found: 269.1402.
(5E)-5-[(4-bromo-1H-indol-3-yl)methylene]-1,3-dimethyl-2-(methylimino)imidazolidin4-one (62): 1H NMR (400 MHz, DMSO) δ 11.83 (s, 1H), 8.69 (s, 1H), 7.47 (d, J = 8.0 Hz, 1H),
7.28 (d, J = 7.5 Hz, 1H), 7.25 (s, 1H), 7.04 (t, J = 7.8 Hz, 1H), 3.18 (s, 3H), 3.06 (s, 3H), 2.73 (s,
3H).

13

C NMR (101 MHz, DMSO) δ 165.24, 156.45, 137.75, 130.63, 129.84, 124.94, 124.43,

123.11, 113.26, 112.41, 109.32, 102.20, 34.41, 34.27, 28.49. HRESMS m/z calcd 347.0507
(M.+ +H); found: 347.0508.
(5E)-5-[(5-bromo-1H-indol-3-yl)methylene]-1,3-dimethyl-2-(methylimino)imidazolidin4-one (63): 1H NMR (400 MHz, DMSO) δ 11.64 (s, 1H), 8.73 (s, 1H), 8.16 (s, 1H), 7.38 (d, J =
8.5 Hz, 1H), 7.25 (d, J = 8.5 Hz, 1H), 6.42 (s, 1H), 3.36 (s, 3H), 3.23 (s, 3H), 2.99 (s, 3H).

13

C

NMR (101 MHz, DMSO) δ 162.39, 152.07, 134.70, 130.05, 129.07, 124.59, 121.23, 114.11,
113.30, 112.77, 109.23, 103.51, 33.03, 31.23, 26.80. HRESMS m/z calcd 347.0507 (M.+ +H);
found: 347.0512.

123

(5E)-5-[(6-bromo-1H-indol-3-yl)methylene]-1,3-dimethyl-2-(methylimino)imidazolidin4-one (64): 1H NMR (400 MHz, DMSO) δ 11.77 (s, 1H), 8.82 (s, 1H), 7.94 (d, J = 7.7 Hz, 1H),
7.65 (s, 1H), 7.27 (d, J = 8.1 Hz, 1H), 6.74 (s, 1H), 3.32 (s, 3H), 3.23 (s, 3H), 3.00 (s, 3H).

13

C

NMR (101 MHz, DMSO) δ 163.20, 153.12, 137.45, 130.91, 130.02, 124.22, 123.07, 114.46,
113.72, 113.08, 110.11, 105.14, 34.01, 30.29, 23.30. HRESMS m/z calcd 347.0507 (M.+ +H);
found: 347.0514.
(5E)-5-[(7-bromo-1H-indol-3-yl)methylene]-1,3-dimethyl-2-(methylimino)imidazolidin4-one (65): 1H NMR (400 MHz, DMSO) δ 11.86 (s, 1H), 8.35 (s, 1H), 7.99 (d, J = 7.9 Hz, 1H),
7.40 (d, J = 7.5 Hz, 1H), 7.09 (t, J = 7.8 Hz, 1H), 6.71 (s, 1H), 3.23 (s, 3H), 2.99 (s, 3H), 2.96 (s,
3H). 13C NMR (101 MHz, DMSO) δ 162.44, 153.30, 141.59, 129.83, 126.62, 126.24, 125.95,
124.11, 120.70, 110.20, 107.78, 105.03, 35.80, 26.73, 24.86. HRESMS m/z calcd 347.0507
(M.+ +H); found: 347.0513.
(Z)-5-[(1H-indol-3-yl)methylene]-2-thioxoimidazolidin-4-one (66): 1H NMR (400 MHz,
DMSO) δ 8.40 (s, 1H), 7.79 (d, J = 7.6 Hz, 1H), 7.43 (d, J = 7.9 Hz, 1H), 7.16 (ddd, J = 14.2,
7.7, 3.8 Hz, 2H), 6.67 (s, 1H).

13

C NMR (101 MHz, DMSO) δ 177.19, 165.91, 136.35, 129.33,

127.56, 123.69, 123.07, 121.13, 118.49, 112.54, 108.73, 105.93. HRESMS m/z calcd 266.0363
(M.+ +Na); found: 266.0359.
(Z)-5-[(4-bromo-1H-indol-3-yl)methylene]-2-thioxoimidazolidin-4-one (67): 1H NMR
(400 MHz, DMSO) δ 12.03 (s, 1H), 8.43 (s, 1H), 7.66 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.33 (d,
J = 7.5 Hz, 1H), 7.09 (t, J = 7.8 Hz, 1H).

13

C NMR (101 MHz, DMSO) δ 177.69, 166.04,

138.05, 131.38, 125.74, 124.27, 124.07, 123.93, 113.39, 112.61, 109.21, 106.49. HRESMS m/z
calcd 343.9468 (M.+ +Na); found: 343.9476.
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(Z)-5-[(5-bromo-1H-indol-3-yl)methylene]-2-thioxoimidazolidin-4-one (68): 1H NMR
(400 MHz, DMSO) δ 12.16 (s, 1H), 8.46 (s, 1H), 8.04 (d, J = 1.2 Hz, 1H), 7.41 (d, J = 8.6 Hz,
1H), 7.30 (dd, J = 8.6, 1.5 Hz, 1H), 6.82 (s, 1H).

13

C NMR (101 MHz, DMSO) δ 177.49,

165.86, 135.10, 130.40, 129.37, 125.59, 124.32, 121.28, 114.48, 113.80, 108.55, 105.29.
HRESMS m/z calcd 343.9468 (M.+ +Na); found: 343.9458.
(Z)-5-[(6-bromo-1H-indol-3-yl)methylene]-2-thioxoimidazolidin-4-one (69): 1H NMR
(400 MHz, DMSO) δ 8.42 (s, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.63 (d, J = 1.5 Hz, 1H), 7.23 (dd, J
= 8.5, 1.6 Hz, 1H), 6.70 (s, 1H).

13

C NMR (101 MHz, DMSO) δ 178.11, 167.27, 137.22,

129.78, 127.05, 126.55, 123.62, 120.58, 115.48, 115.03, 109.59, 104.30. HRESMS m/z calcd
343.9468 (M.+ +Na); found: 343.9460.
(Z)-5-[(7-bromo-1H-indol-3-yl)methylene]-2-thioxoimidazolidin-4-one (70): 1H NMR
(400 MHz, DMSO) δ 11.97 (s, 1H), 8.53 (s, 1H), 7.83 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 7.5 Hz,
1H), 7.07 (t, J = 7.8 Hz, 1H), 6.76 (s, 1H).

13

C NMR (101 MHz, DMSO) δ 177.72, 166.09,

134.83, 130.11, 129.28, 125.60, 124.97, 122.38, 118.19, 109.95, 105.13, 104.80. HRESMS m/z
calcd 343.9468 (M.+ +Na); found: 343.9455.
(Z)-5-[(1H-indol-3-yl)methylene]-2-(methylthio)-1H-imidazol-4(5H)-one (71): 1H NMR
(400 MHz, DMSO) δ 11.85 (s, 1H), 8.37 (s, 1H), 8.15 (d, J = 7.6 Hz, 1H), 7.46 (d, J = 7.8 Hz,
1H), 7.22 – 7.13 (m, 2H), 7.11 (s, 1H), 2.68 (s, 3H).

13

C NMR (101 MHz, DMSO) δ 170.62,

159.79, 136.78, 136.40, 135.36, 132.46, 127.15, 122.87, 120.99, 116.30, 112.57, 111.58, 12.67.
HRESMS m/z calcd 280.0521 (M.+ +Na); found: 280.0505.
(Z)-5-[(4-bromo-1H-indol-3-yl)methylene]-2-(methylthio)-1H-imidazol-4(5H)-one (72):
1

H NMR (400 MHz, DMSO) δ 11.64 (s, 1H), 8.75 (s, 1H), 7.94 (s, 1H), 7.52 (d, J = 8.0 Hz, 1H),
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7.34 (d, J = 7.5 Hz, 1H), 7.08 (t, J = 7.8 Hz, 1H), 2.66 (s, 3H).

13

C NMR (101 MHz, DMSO) δ

170.64, 161.07, 138.01, 135.52, 133.94, 125.75, 124.45, 123.79, 115.56, 113.44, 112.72, 111.57,
12.69. HRESMS m/z calcd 357.9626 (M.+ +Na); found: 357.9614.
(Z)-5-[(5-bromo-1H-indol-3-yl)methylene]-2-(methylthio)-1H-imidazol-4(5H)-one (73):
1

H NMR (400 MHz, DMSO) δ 11.57 (s, 1H), 8.92 (s, 1H), 8.27 (s, 1H), 7.42 (d, J = 8.6 Hz, 1H),

7.30 (d, J = 8.6 Hz, 1H), 7.07 (s, 1H), 2.72 (s, 3H). 13C NMR (101 MHz, DMSO) δ 170.74,
159.91, 136.04, 135.26, 134.60, 128.30, 125.42, 124.52, 116.90, 114.46, 113.65, 111.96, 12.88.
HRESMS m/z calcd 357.9626 (M.+ +Na); found: 357.9610.
(Z)-5-[(6-bromo-1H-indol-3-yl)methylene]-2-(methylthio)-1H-imidazol-4(5H)-one (74):
1

H NMR (400 MHz, DMSO) δ 11.71 (s, 1H), 8.34 (s, 1H), 8.20 (d, J = 8.5 Hz, 1H), 7.65 (d, J =

1.6 Hz, 1H), 7.25 (dd, J = 8.5, 1.7 Hz, 1H), 7.07 (s, 1H), 2.67 (s, 3H).

13

C NMR (101 MHz,

DMSO) δ 170.66, 160.55, 137.74, 135.83, 133.28, 126.05, 123.71, 122.24, 115.74, 115.53,
115.14, 111.84, 12.75. HRESMS m/z calcd 357.9626 (M.+ +Na); found: 357.9612.
(Z)-5-[(7-bromo-1H-indol-3-yl)methylene]-2-(methylthio)-1H-imidazol-4(5H)-one (75):
1

H NMR (400 MHz, DMSO) δ 12.03 (s, 1H), 8.39 (s, 1H), 8.19 (d, J = 7.9 Hz, 1H), 7.39 (d, J =

7.6 Hz, 1H), 7.10 (s, 1H), 7.07 (t, J = 7.8 Hz, 1H), 2.67 (s, 3H).

13

C NMR (101 MHz, DMSO) δ

170.58, 161.01, 136.28, 135.13, 132.93, 128.87, 125.47, 122.30, 119.61, 115.42, 112.77, 105.13,
12.69. HRESMS m/z calcd 357.9626 (M.+ +Na); found: 357.9619.
(Z)-5-[(1H-indol-3-yl)methylene]-2-(methylamino)-1H-imidazol-4(5H)-one (76): 1H
NMR (400 MHz, DMSO) δ 8.16 (s, 1H), 7.85 (d, J = 7.1 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.16
– 7.11 (m, 1H), 7.10 – 7.05 (m, 1H), 6.65 (s, 1H), 2.92 (s, 3H). 13C NMR (101 MHz, DMSO) δ
166.72, 159.00, 136.32, 132.32, 130.41, 127.22, 122.24, 120.06, 118.98, 112.18, 112.05, 109.39,
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28.41. HRESMS m/z calcd 263.0909 (M.+ +Na); found: 263.0906.
(Z)-5-[(4-bromo-1H-indol-3-yl)methylene]-2-(methylamino)-1H-imidazol-4(5H)-one
(77): 1H NMR (400 MHz, DMSO) δ 12.18 (s, 1H), 8.74 (s, 1H), 7.93 (s, 1H), 7.53 (d, J = 7.9 Hz,
1H), 7.37 (d, J = 7.5 Hz, 1H), 7.11 (t, J = 7.9 Hz, 1H), 2.68 (s, 3H). 13C NMR (101 MHz,
DMSO) δ 171.84, 157.01, 138.02, 137.03, 127.37, 124.43, 123.83, 122.83, 121.88, 121.70,
112.76, 111.53, 28.15. HRESMS m/z calcd 341.0014 (M.+ +Na); found: 341.0002.
(Z)-5-[(5-bromo-1H-indol-3-yl)methylene]-2-(methylamino)-1H-imidazol-4(5H)-one
(78): 1H NMR (400 MHz, DMSO) δ 11.63 (s, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 7.36 (d, J = 8.6 Hz,
1H), 7.23 (d, J = 8.3 Hz, 1H), 6.60 (s, 1H), 2.92 (s, 3H).

13

C NMR (101 MHz, DMSO) δ 169.29,

155.11, 137.51, 135.19, 134.16, 132.29, 130.07, 122.25, 117.22, 114.15, 104.76, 104.36, 28.53.
HRESMS m/z calcd 341.0014 (M.+ +Na); found: 341.0002.
(Z)-5-[(6-bromo-1H-indol-3-yl)methylene]-2-(methylamino)-1H-imidazol-4(5H)-one
(79): 1H NMR (400 MHz, DMSO) δ 11.59 (s, 1H), 8.14 (s, 1H), 7.90 (d, J = 6.2 Hz, 1H), 7.60 (s,
1H), 7.18 (d, J = 8.5 Hz, 1H), 6.60 (s, 1H), 2.91 (s, 3H). 13C NMR (101 MHz, DMSO) δ 167.35,
154.29, 137.26, 136.33, 132.23, 126.16, 126.12, 122.93, 114.94, 114.75, 114.34, 100.19, 25.97.
HRESMS m/z calcd 341.0014 (M.+ +Na); found: 341.0007.
(Z)-5-[(7-bromo-1H-indol-3-yl)methylene]-2-(methylamino)-1H-imidazol-4(5H)-one
(80): 1H NMR (400 MHz, DMSO) δ 11.62 (s, 1H), 8.29 (s, 1H), 7.95 (d, J = 7.4 Hz, 1H), 7.36
(d, J = 7.2 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 6.62 (s, 1H), 2.92 (s, 3H).

13

C NMR (101 MHz,

DMSO) δ 168.13, 151.53, 138.79, 136.39, 134.67, 128.92, 124.77, 118.82, 117.42, 110.12,
108.13, 104.86, 28.14. HRESMS m/z calcd 341.0014 (M.+ + Na); found: 340.999
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5-HT1A
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32
33
34
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5-HT1B 5-HT1D 5-HT1E 5-HT2A
1169
4617
58
>10,000 3128
>10,000 2147

36

1413
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3215

>10,000

39

>10,000 >10,000
>10,000
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4158
>10,000
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3445
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2624

>10,000 >10,000
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49
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>10,000
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>10,000
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>10,000
>10,000

6835

7971

>10,000 >10,000

0
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>10,000 >10,000

5-HT2B
232
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1248
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112
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1323
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2332
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1425
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3029
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7828
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1704
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3013
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10000
2339
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742
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1405
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1223

1409
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CMPD

5-HT1A
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>10,000
>10,000 >10,000
2552 >10,000 >10,000

6927
2513
>10,000
>10,000>10,000 8867
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1620
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965
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3350
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10000
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1511
1716
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6470
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66
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68
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71
72

2753

73
74

676

75
76
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287
369
780
50
1676
1346
93
2714
1136
154
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1870
885
80
4348
2094
426

928
2359
1063
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4367
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1156
2214
2345
603

78
79
80

3593

993
353

678

3372

3799
226

3733

860

3324

Table 4-1 Secondary in vitro binding data from compounds 31-80 at all 12 5-HT subtypes

NMR data for compounds 81-92
(E)-5-[(1-benzyl-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (81):
1

H NMR (400 MHz, CDCl3) δ 9.03 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.34 – 7.24 (m, 7H), 7.19

(d, J = 7.3 Hz, 2H), 6.63 (s, 1H), 5.42 (s, 2H), 3.34 (s, 3H), 3.18 (s, 3H).

13

C NMR (101 MHz,

CDCl3) δ 153.42, 145.37, 136.61, 136.14, 132.69, 128.86 (d), 127.83, 126.75 (d), 124.74,
122.71, 120.77, 120.04, 117.77, 110.59, 108.94, 108.73, 50.85, 26.34, 24.60. HRESMS m/z
calcd 345.1715 (M.+ +H); found: 345.1710.
(E)-5-[(1-(4-chlorobenzyl)-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin4-one (82): 1H NMR (400 MHz, DMSO) δ 9.51 (s, 1H), 9.07 (s, 1H), 8.11 (d, J = 6.2 Hz, 1H),
7.60 (d, J = 6.6 Hz, 1H), 7.41 (d, J = 7.5 Hz, 2H), 7.27 (m, 5H), 5.61 (s, 2H), 3.54 (s, 3H), 3.22
(s, 3H).

13

C NMR (101 MHz, DMSO) δ 161.58, 151.42, 138.28, 135.83, 134.12, 133.29, 129.93,

130.48, 130.20, 128.83, 128.24, 122.95, 122.35, 120.72, 118.88, 115.11, 110.73, 108.46, 48.18,
30.45, 28.28. HRESMS m/z calcd 379.1326 (M.+ +H); found: 379.1319.
(E)-5-[(1-(2-chlorobenzyl)-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin4-one (83): 1H NMR (400 MHz, DMSO) δ 9.36 (s, 1H), 9.02 (s, 1H), 8.14 (d, J = 6.5 Hz, 1H),
7.61 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.38 (t, J = 7.4 Hz, 1H), 7.30 (dd, J = 12.7, 5.0
Hz, 4H), 7.05 (d, J = 7.5 Hz, 1H), 5.67 (s, 2H), 3.52 (s, 3H), 3.19 (s, 3H).

13

C NMR (101 MHz,

DMSO) δ 160.64, 152.57, 136.46, 134.57, 134.40, 132.98, 130.33, 130.24, 129.97, 128.73,
128.16, 123.64, 122.97, 121.71, 119.39, 115.18, 111.50, 108.81, 48.22, 29.33, 26.67. HRESMS
m/z calcd 379.1326 (M.+ +H); found: 379.1335.
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(E) -5-[(1-(4-nitrobenzyl)-1H-indol-3-yl)methylene]- 2-imino-1,3-dimethylimidazolidin4-one (84): 1H NMR (400 MHz, DMSO) δ 8.83 (s, 1H), 8.19 (d, J = 8.4 Hz, 2H), 7.95 (d, J =
7.2 Hz, 1H), 7.47 (d, J = 7.5 Hz, 1H), 7.40 (d, J = 8.4 Hz, 2H), 7.24 – 7.11 (m, 3H), 6.44 (s, 1H),
5.69 (s, 2H), 3.27 (s, 3H), 3.06 (s, 3H).

13

C NMR (101 MHz, DMSO) δ 162.67, 150.98, 147.33,

146.16, 135.96, 130.88, 128.84, 128.41(d), 127.58, 124.34(d), 122.77, 120.50, 119.10, 110.83,
109.69, 102.19, 49.19, 27.43, 25.33. HRESMS m/z calcd 390.1566 (M.+ +H); found: 390.1572.
(E) -5-[(1-(2-nitrobenzyl)-1H-indol-3-yl)methylene]- 2-imino-1,3-dimethylimidazolidin4-one (85): 1H NMR (400 MHz, DMSO) δ 8.88 (s, 1H), 8.18 (dd, J = 7.8, 1.2 Hz, 1H), 8.07 –
8.00 (m, 1H), 7.58 (tt, J = 7.4, 6.2 Hz, 2H), 7.51 – 7.46 (m, 1H), 7.21 (p, J = 5.3 Hz, 2H), 6.78 (s,
1H), 6.55 (d, J = 7.5 Hz, 1H), 5.93 (s, 2H), 3.26 (s, 3H), 2.97 (s, 3H).

13

C NMR (101 MHz,

DMSO) δ 162.35, 153.32, 147.71, 136.39, 134.76, 133.84, 132.34, 129.27, 128.69, 128.32,
125.75, 125.61, 123.16, 121.02, 119.16, 111.12, 109.45, 107.54, 47.60, 26.73, 24.76. HRESMS
m/z calcd 390.1566 (M.+ +H); found: 390.1563.
(E)-5-[(5-cyano-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (86):
1

H NMR (400 MHz, DMSO) δ 12.16 (s, 1H), 8.89 (s, 1H), 8.63 (s, 1H), 7.61 (d, J = 8.4 Hz, 1H),

7.52 (d, J = 8.4 Hz, 1H), 6.86 (s, 1H), 3.36 (s, 3H), 3.11 (s, 3H).

13

C NMR (101 MHz, DMSO) δ

161.79, 158.16, 137.84, 136.40, 131.15, 128.02, 126.34, 125.21, 124.89, 121.03, 113.74, 109.94,
102.44, 28.36, 25.97. HRESMS m/z calcd 280.1198 (M.+ +H); found: 280.1201.
(E)-5-[(1-acetyl-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (87):
131

1

H NMR (400 MHz, DMSO) δ 9.67 (s, 1H), 9.22 (s, 1H), 8.36 (dd, J = 6.5, 2.4 Hz, 1H), 8.14

(dd, J = 6.2, 2.5 Hz, 1H), 7.53 – 7.36 (m, 2H), 7.18 (s, 1H), 3.51 (s, 3H), 3.23 (s, 3H), 2.73 (s,
3H).

13

C NMR (101 MHz, DMSO) δ 168.83, 162.30, 150.18, 136.40, 127.08, 126.23, 124.39,

124.08, 120.86, 119.84, 113.68, 109.14, 102.83, 33.36, 29.47, 24.51. HRESMS m/z calcd
297.1352 (M.+ +H); found: 297.1345.
(E)-5-[(5-fluoro-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (88):
1

H NMR (400 MHz, DMSO) δ 11.62 (s, 1H), 8.71 (s, 1H), 8.16 (s, 1H), 7.38 (d, J = 8.6 Hz, 1H),

7.24 (dd, J = 8.5, 1.4 Hz, 1H), 6.42 (s, 1H), 3.25 (s, 3H), 3.05 (s, 3H).

13

C NMR (101 MHz,

DMSO) δ 160.16, 152.02, 134.56, 132.21, 129.61, 125.29, 122.41, 121.22, 115.25, 114.36,
113.75, 108.24, 28.97, 26.28. HRESMS m/z calcd 273.1152 (M.+ +H); found: 273.1151.
(E)-5-[(5-methoxy-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one
(89): 1H NMR (400 MHz, DMSO) δ 11.92 (s, 1H), 9.27 (s, 1H), 8.95 (d, J = 3.0 Hz, 1H), 7.60
(d, J = 2.0 Hz, 1H), 7.40 (d, J = 8.7 Hz, 1H), 7.30 (s, 1H), 6.87 (dd, J = 8.7, 2.3 Hz, 1H), 3.85 (s,
3H), 3.52 (s, 3H), 3.20 (s, 3H).

13

C NMR (101 MHz, DMSO) δ 160.05, 154.97, 151.65, 131.75,

130.71, 128.57, 121.18, 116.29, 113.06, 112.55, 108.51, 100.86, 55.71, 28.98, 26.16. HRESMS
m/z calcd 285.1352 (M.+ +H); found: 285.1358.

(E) -5-[(1-methyl-1H-indol-3-yl)methylene]- 2-imino-1,3-dimethylimidazolidin-4-one
(90): 1H NMR (400 MHz, DMSO) δ 8.81 (s, 1H), 7.98 (d, J = 7.9 Hz, 1H), 7.52 (d, J = 8.0 Hz,
1H), 7.26 (t, J = 7.5 Hz, 1H), 7.19 (t, J = 7.4 Hz, 1H), 6.76 (s, 1H), 3.88 (s, 3H), 3.25 (s, 3H),
3.01 (s, 3H).

13

C NMR (101 MHz, CDCl3) δ 162.66, 152.69, 136.57, 132.11, 128.56, 125.85,
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122.23, 120.17, 117.72, 109.74, 108.34, 104.23, 33.26, 27.03, 24.90. HRESMS m/z calcd
269.1402 (M.+ +H); found: 269.1397.

(E) -5-[(1-ethyl-1H-indol-3-yl)methylene]- 2-imino-1,3-dimethylimidazolidin-4-one (91):
1

H NMR (400 MHz, DMSO) δ 8.88 (s, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.55 (d, J = 8.1 Hz, 1H),

7.21 (dt, J = 25.3, 7.2 Hz, 2H), 6.75 (s, 1H), 4.29 (q, J = 7.2 Hz, 2H), 3.23 (s, 3H), 3.00 (s, 3H),
1.41 (t, J = 7.2 Hz, 3H).

13

C NMR (101 MHz, DMSO) δ 162.37, 153.23, 135.75, 131.18, 128.76,

124.84, 122.62, 120.58, 118.97, 110.78, 108.46, 108.22, 41.35, 26.68, 24.76, 15.66. HRESMS
m/z calcd 283.1559 (M.+ +H); found: 283.1554.
(E) -5-[(1-propyl-1H-indol-3-yl)methylene]- 2-imino-1,3-dimethylimidazolidin-4-one
(92): 1H NMR (400 MHz, DMSO) δ 8.86 (s, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.56 (d, J = 8.0 Hz,
1H), 7.28 – 7.14 (m, 2H), 6.76 (s, 1H), 4.23 (t, J = 6.9 Hz, 2H), 3.24 (s, 3H), 3.01 (s, 3H), 1.89 –
1.75 (m, 2H), 0.87 (t, J = 7.3 Hz, 3H).

13

C NMR (101 MHz, DMSO) δ 162.39, 153.24, 136.40,

136.09, 131.95, 128.67, 124.90, 122.61, 120.54, 118.95, 110.91, 108.30, 48.05, 26.69, 24.77,
23.45, 11.60. HRESMS m/z calcd 297.1715 (M.+ +H); found: 297.1709.
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